Novartis Research and Development
LNP023
Clinical Trial Protocol CLNP023X2202  / [STUDY_ID_REMOVED]
An open -label, non -randomized study on efficacy , 
pharmacokinetics, pharmacodynamics, safety and 
tolerability of LNP023 in tw o patient populations w ith C3 
glomerulopathy
Document type: Amended Protocol Version
EUDRACT number: 2017 -000889 -29
Version number: v03 ( Clean )
Clinical Trial Phase: II
Release date: 07-Feb-2020
Property of Novartis
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of Novartis
Novartis Confidential Page 2
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Site Operations Manual (SOM)
A Site Operations Manual (SOM) accompanies this protocol, providing the operational details
for study  procedures. Note: T he SOM will not be a part of the Clinical Study  Report.
Novartis Confidential Page 3
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Table of contents
Site Operations Manual (SOM)........................................................................................... 2
Table of contents ................................................................................................................. 3
List of tables ........................................................................................................................ 7
List of figures ...................................................................................................................... 7
List of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 11
Protocol summary .............................................................................................................. 19
1Introduction ....................................................................................................................... 24
1.1 Background ............................................................................................................ 24
1.2 Purpose .................................................................................................................. 26
2Objectiv
es and endpoints ................................................................................................... 27
3Study  design ................................ ................................ ................................ ...................... 29
4Rationale ............................................................................................................................ 36
4.1 Rationale for stud y design ..................................................................................... 36
4.1.1 Rationale for choice of background therap y
......................................... 38
4.2 Rationale for dose/regimen and duration of t
reatment .......................................... 38
4.3
Rationale for choice of control drugs (comparator/placebo) or combination 
drugs ...................................................................................................................... 39
4.4 Purpose and timing of interim anal yses/design adaptations ................................ ..40
4.5 Risks and benefits .................................................................................................. 40
4.5.1 Blood sample volume ............................................................................ 41
4.5.2 Potential risks ........................................................................................ 41
4.5.3 Risk for infections ................................................................................. 41
4.5.4 Risk for testis tubular degeneration ....................................................... 42
4.5.6 Non-clinical safet y findings of undetermined relevance ...................... 43
4.5.7 Risk mitigation strategy ........................................................................ 44
5Population .......................................................................................................................... 45
5.1 Inclusion criteria .................................................................................................... 45
5.2 Exclusion criteria ................................................................................................... 47
6Treatment ........................................................................................................................... 51
6.1 Study  treatment ...................................................................................................... 52
6.1.1 Investigational and control drugs .......................................................... 52
Commercially Confidential Information
Commercially Confidential Information (CCI)
Novartis Confidential Page 4
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
6.1.2 Additional study  treatments .................................................................. 52
6.1.3 Treatment arms/group ........................................................................... 52
6.2 Other treatment(s) .................................................................................................. 52
6.2.1 Concomitant therap y
............................................................................. 53
6.2.2
Prohibited medication ........................................................................... 53
6.2.3
Rescue medication ................................................................................ 54
6.2.4 Restriction for study  subjects ................................................................ 54
6.3 Subject numbering, treatment assignment, randomization .................................... 55
6.3.1 Subject numbering ................................................................................ 55
6.3.2 Treatment assignment, randomization .................................................. 55
6.4 Treatment blinding ................................................................................................. 55
6.5
Dose escalation and dose modification.................................................................. 55
6.6 Additional treatment guidance ............................................................................... 55
6.6.1 Treatment compliance ........................................................................... 55
6.6.2 Recommended treatment of adverse events .......................................... 56
6.6.3 Emergency  breaking of assigned treatment code .................................. 56
6.7 Preparation and dispensation ................................................................................. 56
7Informed consent procedures ................................ ................................ ............................ 56
8 Visit schedule and assessments ......................................................................................... 58
8.1 Screening ............................................................................................................... 84
8.1.1 Information to be collected on screening failures ................................. 84
8.2
Subject demographics/other baseline characteristics............................................. 84
8.2.1 Hepatitis screen, HIV screen ................................................................. 84
8.2.2 Tuberculosis status ................................................................................ 84
8.2.4
Renal Biopsies for screening evaluation............................................... 84
8.3 Efficacy /Pharmacody namics ................................................................................. 85
8.3.1 Appropriateness of efficacy  assessments .............................................. 85
8.3.2
24-hours urine c ollection ................................ ................................ .......85
8.3.3 Renal Biopsies for efficacy  evaluation ................................................. 86
8.3.4 Glomer ular filtration rate
...................................................................... 86
8.3.5 Pharmacod ynamic Assessments ............................................................ 86
8.3.6 First 
morning void urine collection ....................................................... 87
8.4 Safety ..................................................................................................................... 87
8.4.1 Laboratory  evaluations .......................................................................... 87
8.4.2 Electrocardiogram (ECG) ..................................................................... 88
8.4.3 Pregnancy  and assessments of fertility ................................................. 88
Commercially Confidential Information
Novartis Confidential Page 5
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
8.4.4 Vital Signs ............................................................................................. 89
8.4.7 Physical Examination ............................................................................ 90
8.4.9 Vaccination ........................................................................................... 90
8.5
Additional assessments.......................................................................................... 91
8.5.1 Clinical Outcome Assessments (COAs) ............................................... 91
8.5.2 Pharmacokinetics .................................................................................. 91
8.5.3 Biomarkers ............................................................................................ 92
9Study  discontinuation and completion .............................................................................. 94
9.1 Discontinuation ...................................................................................................... 94
9.1.1 Discontinuation of study  treatment ....................................................... 94
9.1.2 Withdrawal of informed consent ........................................................... 95
9.1.3 Lost to follow -
up................................................................................... 96
9.1.4 Study  stopping rules
.............................................................................. 96
9.1.5 Early study termination by the sponsor ................................................. 97
9.2 Study  completion and post -study  treatment .......................................................... 97
10Safety  monitoring and reporting ................................ ................................ ........................ 97
10.1 Definition of adverse events and reporting requirements ...................................... 97
10.1.1 Adverse events ...................................................................................... 97
10.1.2 Serious adverse events .......................................................................... 99
10.1.3 SAE reporting
...................................................................................... 100
10.1.4 Pregnancy  reporting ............................................................................ 101
10.1.5 Reporting of stud y treatment errors including misuse/abuse .............. 101
10.2 Additional Safety  Monitoring .............................................................................. 102
10.2.1 Liver safety  monitoring ....................................................................... 102
10.2.2 Renal safet y monitoring ...................................................................... 102
10.2.3 Infection Surveillance
......................................................................... 103
11Data Collection and Database management .................................................................... 103
11.1
Data collection..................................................................................................... 103
11.2 Database management and quality  control .......................................................... 104
11.3 Site monitoring .................................................................................................... 104
12Data analy sis and statistical methods ................................ ................................ .............. 105
12.1 Analy sis sets ........................................................................................................ 105
12.2
Subject demographics and other baseline characteristics.................................... 105
Commercial ly Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 6
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
12.3 Treatments ................................ ................................ ................................ ........... 106
12.4 Analy sis of the primary  endpoint(s) .................................................................... 106
12.4.1 Definition of primary  endpoint(s) ....................................................... 106
12.4.2 Statistical model, hy pothesis, and method o f anal ysis........................ 106
12.4.3 Handling of missing values/censoring/discontinuations ..................... 107
12.4.4 Sensitivity  analy ses............................................................................. 107
12.5 Analy sis of secondary  endpoints ......................................................................... 107
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................. 108
12.5.2 Safety  endpoints .................................................................................. 108
12.5.3 Pharmacokinetics ................................................................................ 109
12.5.4 Biomarkers .......................................................................................... 110
12.5.5 PK/PD relationships ............................................................................ 110
12.6 Analy sis of exploratory  endpoints ....................................................................... 110
12.7 Interim anal yses................................................................................................... 112
12.8
Sample size calculation........................................................................................ 113
12.8.1 Primary  endpoint(s) ............................................................................. 113
13Ethical considerations and administrative procedures .................................................... 113
13.1 Regulatory
 and ethical compliance ...................................................................... 113
13.2 Responsibilities of the investigator and IRB/ IEC................................................ 113
13.3 Publication of study  protocol and results ............................................................. 113
13.4 Quality  Control and Quality  Assurance ............................................................... 114
14Protocol adherence .......................................................................................................... 114
14.1 Protocol Amendments ......................................................................................... 114
15References ................................ ................................ ................................ ....................... 115
16Appendices ...................................................................................................................... 118
Commercially Confidential Information
Novartis Confidential Page 7
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
List of tables
Table 1-1 Clinical presentation and outcome of patients with dense deposit 
disease and C3 glomerulopathy ............................................................ 26
Table 2
-1 Objectives and related endpoints .......................................................... 27
Table 6
-1 Overview of study  medication .............................................................. 52
Table 8
-1 Assessment Schedule, Cohort A ........................................................... 59
Table 8
-2 Details for highly  repetitive assessments, Cohort A ............................. 68
Table 8-3 Assessment Schedule, Cohort B ........................................................... 71
Table 8
-4 Details for highly  repetitive assessments, Cohort B ............................. 81
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ....................................................................................... 101
Table 16
-1 Liver Event and Laboratory  Trigger Definitions ................................ 118
Table 16-2 Follow Up Requirements for L iver Events and Laboratory  Triggers .119
List of figures
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 8
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
List of abbreviations
ACE Angiotensin converting enzy me
ACEi Angiotensin converting enzy me inhibitor
AE adverse event
aHUS atypical hemolytic uremic syndrome
ALP alkaline phosphatase
ALT alanine aminotransferase
AP Alternative pathway
ARB Angiotensin receptor blocker
AST aspartate aminotransferase
BUN blood urea nitrogen
C3 Component 3
C3G Component 3 glomerulopathy
C3GN C3 glomerulo nephritis
CAP Complement Alternative Pathway
CDRD Complement driven renal diseases
CK creatinine kinase
CKD Chronic kidney disease
CKD -EPI Chronic kidney disease epidemiology
CLr Renal plasma clearance
CMO&PS Chief Medical Office & Patient Safety
COA Clinical outcome assessments
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTC Common Toxicity Criteria
CTT Clinical trial team
CV coefficient of variation
DDD Dense deposit disease
DDE Direct data entry
DHT Dihydrotestosterone
ECG Electrocardiogram
eCRF Electronic case report forms
EDC Electronic Data Capture
eGFR Estimated glomerular filtration rate
EMA European Medicine Agency
EOS End of study 
eSource Electronic Source
ESRD End-stage renal disease
FDA Food and Drug Administration
Commer cially Confidential Information
Commercially Confidential I nformation
Commercially Confidential Information
Novartis Confidential Page 9
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
GCP Good Clinical Practice
GGT Gamma -glutam yl transferase
GLP Good laborator y practices
h hour
HbsAg Hepatitis B surface antigen
HBV Hepatitis B virus
hCG Human chorionic gonadotropin
HCV Hepatitis C virus
HIV human immunodeficiency virus
IB Investigator's brochure
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IgAN IgA nephropathy
INR International Normalized Ratio
IRB Institutional Review Board
KDIGO Kidney Disease Improving Global Outcomes
Kg kilogram
LDH lactate dehydrogenase
LFT Liver function test
MAR Missing at random
MedDRA Medical dictionary for regulatory activities
mg mi lligram (s)
mL mi lliliter(s)
MMRM Mixed model repeated measures
MN Mem branous nephropathy
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PNH Paroxysmal nocturnal hemoglobinuria
POC Proof of concept
ppm parts per million
PT prothrombin time
RBC red blood cell(s)
RNA Ribonucleic acid
SAE serious adverse event
SAP Statistical analysis plan
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially C onfidential Infor mation
Novartis Confidential Page 10
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
sCR serum creatinine
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic py ruvic transaminase
SOM Site Operations Manual
SOP Standard operation procedure
SUSAR Suspected Unexpected Serious Adverse Reactions
TBL total bilirubin
TMA Thrombotic microangiopathy
UA Urine albumin
UACR Urine albumin to creatinine ratio
Ue Urinar y excretion
ULN upper limit of normal
UP Urine protein
UPCR Urine protein to creatinine ratio
VLDL-C Very low density lipoprotein -cholesterol
WBC white blood cell(s)
WHO World Health Organization
Commercially Confidential I nformation
Novartis Confidential Page 11
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Glossary  of terms
Assessment A procedure used to generate data required by the study
Cohort A specific group of subjects fulfilling certain criteria
Control drug Any drug(s) (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the investigational drug being tested in the trial
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data 
using data collection s ystems, such as Web-based applications, interactive 
voice response systems and clinical laboratory interfaces. 
EDC in cludes the use of Electronic Case Report Forms (eCRFs) which are 
used to capture data transcribed from paper source forms used at the point of 
care.
Enrollment Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. pri or to starting any of the procedures described in the protocol)
Epoch Interval of time in the planned conduct of a study. An epoch is associated with 
a purpose (e.g. screening, randomization, treatment, follow -up) which applies 
across all arms of a study.
eSource eSource Direct Data Entry (DDE) refers to the capture of clinical study data 
electronically, at the point of care. eSource combines source documents and 
case report forms (eCRFs) into one application, allowing for the real time 
collection of clin ical trial information to sponsors and other oversight 
authorities, as appropriate.
Investigational 
drugThe study drug whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug,” "Investigational Medicinal 
Product," or “test substance”
Patient An individual with the condition of interest
Personal Data Subject information collected by the Investigator that is transferred to Novartis 
for the purpose of the clinical trial. This data includes subject identifier 
information, study information and biological samples.
Randomization 
numberA unique identifier assigned to each randomized subject, corresponding to a 
specific treatment arm ass ignm ent
Run in Failure A subject who is screened but not randomized/treated after the run- in period 
(where run -in period requires adjustment to subject’s medications or other 
intervention)
Screen Failure A subject who is screened but is not treated or ra ndomized
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource
Study treatment Anydrug or combination of drugs administered to the study participants as 
part of the required study procedures; includes investigational drug(s), 
control(s) or background therapy
Study treatment 
discontinuationWhen the subject permanently stops taking stu dy treatment prior to the 
defined study treatment completion date
Treatment number A unique identifier assigned in non- randomized studies to each dosed subject, 
corresponding to a specific treatment arm 
Novartis Confidential Page 12
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study
Withdrawal of 
study consentWithdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer, and does not allow any further 
collection of personal data.
Novartis Confidential Page 13
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 14
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 15
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 16
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential I nformation
Novartis Confidential Page 17
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 18
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 19
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Protocol summary
Protocol number CLNP023X2202
Full Title An open -label, non -randomized study  on efficacy , pharmacokinetics, 
pharmacodynamics, safety  and tolerability of LNP023 in two patient 
populations with C3 glomerulopathy
Brief title Study on efficacy and safety of LNP023 in C3 glomerulopathy patients 
transplanted and not transplanted
Sponsor and 
Clinical PhaseNovartis Institutes for BioMedical Research / Phase II
Investigation type Drug
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to assess the clinical efficacy , 
pharmacodynamics, safety , tolerability and pharmacokinetics of LNP023 in 
patients with C3 glomerulopathy (C3G) and to evaluate the effect of 
different doses of LNP023 on complement biomarkers 
 C3G patients who have not received a kidney transplant and 
have reduced C3 blood levels will be included in Cohort A of this study; 
C3G patients who have received a kidney tran splant and have C3G 
recurrence will be included in Cohort B.
Primary 
Objective(s)Cohort A: To evaluate the efficacy  of LNP023 in reducing proteinuria at
Week 12
Cohort B: To assess histopathological changes in kidney biopsies at
Week 12
Secondary 
Objectives
All Cohorts: To assess the relationship between LNP023 dose and
proteinuria
All Cohorts: To assess the effect of LNP023 on renal function
All Cohorts: To assess the effect of LNP023 on alternative complement
pathway hyperactivity
All Cohorts: To assess the safety and tolerability of LNP023
All Cohorts: To assess the plasma and urine pharmacokinetics of
LNP023 in patients with C3G
Cohort B: To evaluate the efficacy  of LNP023 in reducing proteinuria at
Week 12
Commercially C onfidential Information
Commercially Confidential Information
Novartis Confidential Page 20
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Study design The study is a non -confirmatory, open -label, two cohort single arm, non-
randomized , study  evaluating the efficacy, safety, tolerability, 
pharmacokinetics, pharmacodynamics and dose/biomarker relation of 
LNP023 in two patient populations: non -transplanted C3G patients with 
reduced C3 serum levels 
enrolled in Cohort A and patients who have undergone kidney 
transplantation and have C3G recurrence, enrolled in Cohort B. Cohort B 
will start in parallel to Cohort A.
On  completion of Treatment period
the patient can:
-roll-over directly in the extension study
or
 proceed to follow -up period.
Population Approximately 15 C3G patients (male or female) with native kidneys and 
with reduced serum C3 levels w ill be enrolled in Cohort A to ensure that 12 
patients complete th estudy in this Cohort.
Approximately 12 C3G kidney transplanted patients with C3G recurrence 
(male or female) will be enrolled in Cohort B to ensure that at least 10 
complete the study in this Cohort.
Key Inclusion 
criteriaPart 1
Cohort A
Patients (females and males 18 years or older in age) must have C3G
as confirmed by renal biopsy within twelve months prior to enrollment
(confirmation by the Investigator is required).
C3G patients with reduced C3 at screening
are eligible for this study.
Estimated GFR (using the CKD -EPI formula)  ≥30 mL/min per 1.73 m2
for patients on a maximum recommended or maximum to lerated dose
of an angiotensin converting enzy me inhibitor (ACEI) or angiotensin
receptor blocker (ARB).
UPCR ≥ 100 mg/mmol sampled from firs t morning void (or≥1 g/24h
total urinary protein excretion from a 24h urinary collection during run -
in) at run-in(Visit 20) orat baseline (Visit 30).
Any antiproteinuric medication (e.g., angiotensin converting enzy me
inhibitors, angiotensin II receptor blockers) must be at a stable dose for
at least 30 days prior to treatment start.

Commercially Confidential Information
Commercially Confidential Information
CCI
Commercially Confidential Information
CCI
Commercially Confidential Information
Novartis Confidential Page 21
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Cohort B
Patients (females and males 18 years or older in age) must have C3G
recurrence after transplantation as confirmed by renal biopsy after
transplantation within twelve months prior to enrollment (confirmation
by the Investigator is required).
Normal or elevated urinary protein excretion at screening or at baseline
(Visit 30).


If applicable, induction treatment after allotransplantation needs to be
completed > 30 day s before inclusion. Any commercially available
induction agent is permitted.
Patients need to be on a stable dose of immunosupp ressive regimen
prior to Day 1. Any  commercially available treatments are allowed for
this purpose (if not prohibited as per protocol ).
Transplantation of a kidney allograft >30 day s before screening
No histologic signs of allorejection
Commercially Confidential Information
Commer cially Confidential Information
Commercially Con fidential Information
Commercially Co nfidential Information
Novartis Confidential Page 22
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Key Exclusion 
criteriaCohort A
Known family history or known presence of long QT syndrome or
Torsades de Pointes.
Pregnant or nursing (lactating) women, where pregnancy  is defined as
the state of a female after conception and until the termination of
gestation, confirm ed by a positive hCG laboratory test
Donation or loss of 400 mL or more of blood within eight (8) weeks
prior to initial dosing, or longer if required by local regulation.
Plasma donation (>200 mL) within 30 days prior to first dosing.
Patients who cannot receive vaccinations against N. meningitidis , S.
pneumoniae , or H. influenzae .
Use of other investigational drugs at the time of enrollment, or within 5
half-lives, or within 30 days of screening , whichever is longer; or longer
if required by local regulat ions.
Cohort B
Known family history or known presence of long QT syndrome or
Torsades de Pointes.
Pregnant or nursing (lactating) women, where pregnancy  is defined as
the state of a female after conception and until the termination of
gestation, confirmed by a positive hCG laboratory test.
Patients who cannot receive vaccinations against N. meningitidis , S.
pneumoniae , or H. influenzae .
Use of other investigational drugs at the time of enrollment, or within 5
half-lives, or within 30 days of screening , whichever is longer; or longer
if requi red by  local regulations.
Study treatment LNP023
Efficacy 
assessmentsCohort A: Reduction from baseline in UPCR at W eek 12
Cohort B: Change from baseline in C3 Deposit Score (based on 
immunofluorescence microscopy )
Pharmacodynamic 
assessmentsThe second ary variables supporting the secondar y objective to assess the 
effect of LNP023 on renal function are UA, UACR, UP, UPCR, serum 
creatinine, creatinine clearance, eGFR (using the CKD -EPI formula), 
hematuria, blood levels of Bb.
Pharmacokinetic 
assessmentsPlasma PK parameters: Non-compartmental analysis and calculation of PK 
parameters based on total LNP023 concentrations, including but not limited 
to Tmax, Cmax, AUClast and AUCtau, as well as Ctrough (Cmin) after 
multiple doses
Urine PK parameters: Non-compartmental analysis of parameters including 
total cumulative urinar y excretion ( Ue) and renal plasma clearance (CLr) of 
LNP023 .
Key safety 
assessmentsECG, vital signs, safety laboratory assessments 
, AEs and SAEs.
Commercially Confidential Information
CCI
Novartis Confidential Page 23
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Other assessments
Data analysis Statistical Analy sis: The data analy sis includes data generated from 
Screening, Treatment period  and safety Follow -up periods. 
Cohort A
The primary variable for assessing the effect of LNP023 is the log ratio to 
baseline UPCR derived from the 24h urine collections at Week 12.
A mixed model repeated measures (MMRM) will be fitted to the log ratio to 
baseline UPCR values over time. The model will include the log ratio to 
baseline UPCR as the depende nt variable, time point (as study day relative 
to the start of study  treatment) as a fixed effect, and baseline log transformed 
UPCR as a fixed covariate.
Baseline is defined to be the 24-hour urine collection on Day -1 to Day 1. 
An unstructured covariance matrix will be used.
Results from this modelling will be presented as the estimated mean value 
of log UPCR at week 12 together with the 80% confidence interval. 
Theresults will be back transformed toprovide the geometric mean and their 
80% CIs on the original scale.
Cohort B
The primary  variable for assessing the histopathological changes in kidney  
biopsies is W eek 12 change from baseline in C3 Deposit Score.
The Wilcoxon signed rank test will be used for C3 Deposit Score data at 
Week 12to compare the median difference of change from baseline. 
TheHodges -Lehmann estimate and 80% confidence interval for the m edian 
difference will be provided.
More details on Statistical analysis will be discussed in detail in the SAP.
Key words C3G, C3 g lomerulopathy
Commercially Confidential Information
CCI
Commercially Confidential Information
Novartis Confidential Page 24
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
1 Introduction
1.1 Background
Approximately  10% of the population worldwide is affected by  chronic kidney  disease (CKD) 
and millions die each year due to the lack of available or effective treatment 
(Webster et al 2017 ). Over 2 million people have end -stage renal disease (ESRD) 
(JhaandRathi 2013 ) and are dependent on dialysis for their survival or have undergone kidney 
transplantation (Couser etal2011 ). CKD results from renal diseases with different underl ying 
molecular m echanisms and with a wide range of rates of progression. Many  of the renal diseases 
that progress to CKD and ESRD are characterized by  inflammation and involve dy sregul ation 
of the complement s ystem.
The complement pathway  is important for innate and adaptive immunity . Inherited and acquired 
dysregulation of the complement alternative pathway  (AP) plays an important role in many 
renal diseases, almost all of which show signs of complement AP dysregulation in renal biopsies 
(Mathern andHeeger 2015 ). Complement driven renal diseases (CDRD) for which there is 
strong s cientific evidence for complement AP dysregulation include component 3 
glomerulopath y (C3G) (Barbour et al 2013 ), IgA nephropath y (IgAN) (Floege et al 2014 , 
Maillard et al 2015 ) and membranous nephropathy  (MN) (Ruggenenti etal2007 ). There are 
limited ( mostly  symptomatic) therapies available to treat these diseases, which generally 
progress to CKD and ESRD. In some patients, the progression towards ESRD takes a decade 
or two, but for a subset of patients the rate of progression is much faster, reducing the quality  
of life and shortening life expectancy . The risk of these diseases returning after kidney 
transplantation is also very high.
There is a high unmet medical need for new therapies to treat CDRD and therapies that target 
the complement system represent a promising approach. Novartis is investigating LNP023, a 
novel oral factor B inhibitor. Factor B (FB) is an essential component of the AP; blockade of 
the AP through FB inhibi tion is expected to be therapeutically  beneficial in CDRD through 
improvement in renal morphology  and function and prevention of further disease progression 
(Kościelska -Kasprzak et al 2014 ). LNP023 is being developed toaddress the unmet need in 
patients w ith CDRD and will initially  be developed for the treatment of C3G, IgAN and MN, 
all orphan diseases.
C3 glomerulopathy  is a rare inflammatory  kidney disease caused by genetic mutations in the 
alternative pathway of the complement s ystem, or by autoantibodies (C3Nefs) that stabilize the 
C3 convertases that leads to dysregulation of the alternative pathway  with consumption of the 
C3 of the complement system and coating of glomeruli with C3 fragments, responsible for 
inflam mation and destruction of renal tissue.
The diagnosis of C3G is established by  renal biopsy  showing dominant C3 deposition. I n most 
cases (60%) autoantibodies are found that stabilize C3 convertase but approximately  40% of 
patients have mutations in the genes for factor H, FB, or C3, or abnormal factor H related 
proteins (Nester andSmith 2016 , Goodship et al 2017 ). Worldwide, the prevalence of C3G is 
8-12 per million ( Thomas et al 2014 ) and the annual incidence is 1 -2 per million per year, with 
an estimated 3 ,910 patients in the United States (US) and 3,222 patients in the Europe Union 
(EU) ( Riedl etal2017 ).
Novartis Confidential Page 25
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
C3G exists in two forms: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) with 
a ~3:1 ratio in prevalence (refer to Table 1-1), respectivel y. DDD is mainly  a pediatric disease, 
with an average age of diagnosis o f 12 years (range 8-20), while the more common form C3GN 
mainly  affects adults (average age at diagnosis 26, range 12 -53) ( Medjeral -Thomas et al 2014). 
Diagnosis is based on renal biopsy  which demonstrates glome ruli t hat contain C3 fragments 
(iC3b, C3c and C3dg) in abundance without immunoglobulin (Pickering et al 2013 ). 
Glomerular histology  may show a range of features: m embranoproliferative, mesangial 
proliferative, or endoc apillary  proliferative and there may be glomerular crescents as well. C3G 
patients also have reduced serum levels of C3, FB and properdin and elevated levels of Ba, Bb, 
C3a, C3d and C5b9 ( Zhanget al 2014 ).
Although som e patients with C3G may  have mild disease with as ymptomatic micro -hematuria 
and/or proteinuria, the majority  of patients have severe, rapidl y progressive disease with a 
nephritic or nephrotic syndrome and renal impairment. In fact, 33% of C3G patients progress 
to E SRD within 6 years and 50% of patients progress to ESRD within 10 years 
(Medjeral -Thomas et al 2014 ). The disease often recurs after renal transplantation (~80% risk), 
limiting t he use of this modality , and thereby reducing the life expectancy  of C3G patients. 
Patients often experience fatigue and exercise intolerance due to the underly ing inflammation 
and anemia often accompanied by  proteinuria, hematuria, hy pertension, and sometimes severe 
edema (Table 1-1). For these reasons, patients also experience detrimental and life-altering 
changes in their psy chological, social, educational and vocational development. Some patients 
with C3G also develop drusen, which is a form of macular deg eneration that can impair vision 
(Savige et al 2016 ). There is also an increased risk for thrombotic microangiopath y (TMA) in 
patients w ith C3G and their descendants. In a French study  for example, 17% of C3G patients 
developed TMA after transplantation ( Servais etal2012 ).
There is currentl y no approved treatment for C3G. Steroids and supportive treatment using 
angiotensin converting enzy me (ACE) inhibitors or angiotensin receptor blockers (ARBs) are 
employ ed with very limited effectiveness. Recommendations from a "Kidney  Disease: 
Improving Global Outcomes" (Couser et al 2011 ) Controversies Conference have been 
published recentl y (Goodship et al 2017 ). The report provides treatment approaches for the 
practical management of C3G patients in the absence of specific therap y. Th ese approaches are 
primarily  based on expert opinion with limited support from retrospect ive studies. With the 
awareness of the importance of AP for C3G disease, treatment with eculizumab has been tried 
in an increasing number of patients. Eculizumab is a humanized monoclonal antibody  that 
inhibits the cleavage of C5 and the formation of the terminal MAC (C5b- 9). It is approved by 
the Food and Drug Administration (FDA) and the European Medicines Agency  (EMA) for the 
treatment of paroxy smal nocturnal hemoglobinuria (PNH) and atypical hemoly tic uremic 
syndrome (aHUS). Despite the fact that eculiz umab does n ot reduce AP activation it seems to 
ameliorate symptoms in ~50% of patients with C3G (Bomback andRadhakrishnan 2014 , 
Bomback et al 2012 ) confirming involvement of the complement p athway  in this disease. 
However, eculizumab blocks terminal complement activation. Therefore, patients may have 
increased susceptibility  to infections especiall y with encapsulated bacteria (Soliris EU SMPC). 
By contrast, LNP023 is a specific inhib itor of the AP pathway  and as such should provide 
similar or greater efficacy  in C3G patients with an improved safety  profile. That is, the classical 
and lectin complement pathway s remain functional in the presence of LNP023 and therefore 
should provide a lower risk of infection. Indeed, data supporting an intact serological response 
Novartis Confidential Page 26
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
to Neisseria infection during AP-blockade and a drastic ally reduced response durin g 
C5-blockade were recently  presented ( Konar andGranoff 2017).
Table 1
-1 Clinical presentation and outcome of patients with dense deposit 
disease and C3 glomerulopathy
Clinical presentation / outcome Dense deposit disease C3 glomerulopathy
Prevalence (ppm) 1-2 7-10
Incidence (ppm/year) 0.2-0.4 0.8-1.6
Pediatric onset (<16 years) 43-70 % 25-54 %
Mean age at onset (years) 19 ± 18 30 ± 19
Clinical presentation
Nephrotic syndrome 38-43 % 27-44 %
Micro -hematuria 76-84 % 65 %
Arterial hypertension 21-60 % 40 %
Impaired renal function (>1.5 mg/dL 
creatinine)29 % 50 %
Low C3 (<75 mg/dL) 59-79 % 40-48 %
Long -term outcome
Average duration to end -stage renal 
disease ( years)10 ± 11 11 ± 10
Estimated risk of recurrence of disease 
after kidney transplantation*70-90% 60-80%
Table modified from (Riedl et al 2017 ). *Data based on limited number of studies 
(Salvadori and Bertoni 2016 )
There is a clear unmet medical need in this orphan condition for which there is no approved 
therap y and which often exhibits a rapidly  progressive course leading to end stage renal disease, 
a dramatic reduction in life expectancy  and a highly  negative impact on the quality  of life.
1.2 Purpose
The purpose of this study  is to assess the clinical efficacy , pharmacody namics, safet y, 
tolerability  and pharmacokinetics of LNP023 in patients with C3 glomerulopathy (C3G) and to 
evaluate the effect of different doses of LNP0 23 on complement biomarkers 
. C3G patients who have not received a kidney transplant and have 
reduced C3 blood levels will be included in Cohort A, C3G patients who have received a kidney 
transplant and have C3G recurrence will be included in Cohort B.
CCI
Commercially Confidential Information
Novartis Confidential Page 27
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
Cohort A :To evaluate the efficacy  of
LNP023 in reducing proteinuria at
Week 12Ratio to baseline of Urine Protein to Creatinine
concentration Ratio (UPCR) derived from 24h
urine collection.
Cohort B: To assess histopathological
changes in kidney biopsies at Week 12Change from baseline in C3 Deposit Score
(based on immunofluorescence microscopy ).
Secondary objective(s) Endpoint(s) for secondary objective(s)
All Cohorts :To assess the
relationship between LNP023 dose and
pharmacodynamic biomarkersBiom arker levels of blood Bb
All Cohorts :To assess the
relationship between LNP023 dose and
proteinuria24h urine UPCR and UACR.
All Cohorts :To assess the effect of
LNP023 on renal function(i) change in and (ii) evolution of: urinary albumin
(UA), urinary protein (UP) excretion; urine
albumin to creatinine ratio (UACR) urine protein
to creatinine ratio (UPCR), serum creatinine,
estimated glom erular filtration rate (eGFR, using
CKD -EPI formula), creatinine clearance,
hematuria
All Cohorts :To assess the effect of
LNP023 on alternative complement
pathway hyperactivityBlood level of C3.
All Cohorts :To assess the safety and
tolerability of LNP 023ECG parameters, vital signs, safety  laboratory
assessments , 
AEs and SAEs.
All Cohorts :To assess the plasma
and urine pharmacokinetics of LNP023
in patients with C3GPlasma: Non -compartmental parameter analysis
related to total drug, including but not limited to
Cmax, Tmax, AUClast, AUCtau and Ctrough
(Cmin) after the first dose on Day 7, Day 14, Day
21 and Day 28, as well as Cmin on Day s 92, and
99or 176and 1 83.
Urine: Non -compartmental parameters, including
but not limited to total cumulative urinary
excretion ( Ue) and renal plasma clearance (CLr).
Cohort B:   To evaluate the efficacy  of
LNP023 in reducing proteinuria at
Week 12Ratio to baseline of UPCR and UACR derived
from 24h urine collection.
CCI
Novartis Confidential Page 28
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Objective(s) Endpoint(s)
Commercially Confidential Infor mation
Novartis Confidential Page 29
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
3 Study  design
The study  is a non confirmatory , open -label, two cohort single arm, non-randomized study 
evaluating the efficacy, safet y, tolerability , pharmacokinetics, pharmacod ynamics and 
dose/biomarker relation of LNP023 in two patient populations: non -transplanted C3G patients 
with reduced C3 serum levels (<0. 90x lower limit of the lab normal range) , enrolled in Cohort 
A andpatients who have undergone kidney  transplant and have C3G recurrence, enrolled in 
Cohort B. Cohort B will start in parallel to Cohort A.
Cohort A
Approximately  15 patients will be enrolled in Cohort A to ensure that at least 12 patients 
complete the study  in this cohort.
The study  consists of (refer to Figure 3-1):
A screening period that lasts up to 60 day s and it is made up by  a screening visit and a
run-
in period
 During the run -in 
period, first morning void urine collection will be performed one time. It may  be 
substituted by  a 24h urine collection. A renal biopsy  may  be taken at any  time during the 
screening period to confirm C3G diagno sis, if the most recent biopsy  is older than 12 
months.
A baseline period of about 30 day s, made up by  two visits. During this period baseline
values for key complement biomarkers, as per objectives, and efficacy  related proteinuria
will be established. Patients during baseline should be under stable doses of supportive
therap y (antihypertensive and antiproteinuric therapy, e.g., angiotensin converting enzyme
inhibitors, angiotensin II receptor blockers,
as per KDIGO guidelines; KDIGO 2012 ).
 Last bas eline visit will be 
performed the day  before first dosing.
Treatment period of 12weeks 
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
CCI
Novartis Confidential Page 30
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Follow -up period: A  12 weeks ofsafety
follow -up without t reatment. At the end of Treatment period  if the Investigator
does not deem it to be clinically  beneficial for the patient to continue treatment, or if a
patient does not want to continue treatment, the patient will enter the follow -up period.
A safet y follow- up period of 12 weeks ,without treatment, will follow. There will be
3outpatient visits on Day s 113, 127 and 155
An end -of-study  (EOS) visit is scheduled on Day 183
Patients will remain on their supportive therap y, i.e. ACEi and/or ARB or other antihy pertensive 
therap y, 
 for the duration of the trial. To be dosed, patients must have been on stable therap y with 
an ACEi and/or ARB, 
During the treatment 
period, no change in medication is allowed 
except for safety  reasons.
Patients must receive vaccinations against N. meningitidis , S. pneumoniae and H. influenzae
prior to first LNP023 dosing. 
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
 Commercially Confidential Information
Novartis Confidential Page 31
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Efficacy  in terms of proteinuria and individual clinical response to various pharmacod ynamic 
markers as well as pharmacokinetics will be assessed over the 12 week treatment period 
(refer to Table 8 -1and Table 8
-2the assessment schedule for detailed sampling time).
Commercially Confidential Information
Novartis Confidential Page 32
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
In this context, proteinuria will be assessed by collecting 24-h urine andfirst morning void urine 
to assess the change in and evolution of: UA and UP excretion, UACR and UPCR, creatinine 
clearance and hematuria. 
Safety  monitoring includes the following assessments for each visit during Treatment period
and alerts will be set up for abnormal 
values to be reported immediatel y 
to Investigator and Sponsor:
Renal function surveillance including serum creatinine, eGFR (using the CKD -EPI
formula), hematuria, UA, UACR and UPCR assessments (refer to Section 8.3)
Blood pressure (refer to Section
8.4.4.2)
12-lead ECG (PR interval, QRS duration, heart rate, RR, QT, QTcF, refer to
Section
8.4.2)
Infection surveillance (refer to Section 10.2.3)
Liver safety  (ALT, AST, AL P, TBL, PT/INR, γGT 
levels, refer to Section 10.2.1 )
Hematology  and blood chemistry  parameters (refer to Section 8.4.1)
Vital signs (refer to Section
8.4.4)
Physical examination (refer to Section 8.4.7)
AEs and SAEs recording (refer to Section
10)
Commercially Confidential Information
CCI
Commercially C onfidential Information
Commercially Confidential Information
Novartis Confidential Page 33
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Cohort B
Approximately  12 patients will be enrolled in Cohort B to ensure that at least 10 patients 
complete the study  in this Cohort.
The study  consists of (refer to Figure 3-3 ):
A screening period that lasts up to 60 days and consists of a screening visit and a run- in
period.
. 
During the run -in period first morning void urine collection will be performed one time. It 
may be substituted by  a 24h urine collection. Arenal biopsy  may  be taken at any  time 
during the run
-in period as baseline, if the most recent biopsy  is older than 3 months.
A baseline period of about 30 day s, made up by  two visits. During this period baseline
values for key  complement b iomarkers, as per objectives, and efficacy related proteinuria
will be established. Patients during baseline should be under stable doses of supportive
therap y (antihypertensive and antiproteinuric therapy, e.g., angiotensin converting enzyme
inhibitors, a ngiotensin II receptor blockers, as per
KDIGO guidelines KDIGO 2012).
Last baseline visit will be performed the day  before dosing.
Treatment period  of 12weeks : 
Commercially Confidential Information
CCI
Commercially Confidential Information
CCI
Commercially Confidential Information
Novartis Confidential Page 34
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Follow -up period: A  12 weeks of safety
follow -up without treatment. At the end of Treatment period  if theInvestigator
does not deem it to be clinically  beneficial for the patient to continue treatment, or if a
patient does not want to continue treatment, the patient will enter the follow- up period.
(refer to Figure 3-2 ).
A safety  follow -up period up to 12 weeks with 3outpatient visits on Day s 113, 127and 1 55
An end of stud y visit scheduled on Day 183
The renal biopsy  to be collected during run-in is mandatory  in case the most recent bioptic 
material is older than 3 months. The renal biops y to be collected at Week 12 is mandatory.
Patients will remain on their supportive therap y, i.e. ACEi and/or ARB or other antihypertensive 
therap y,  for the duration of the trial. 
To be dosed patients must have 
been on stable therap y with an ACEi and/or ARB,
During the treatment period, no change in medication is allowed except for safet y 
reasons.
Patients must receive vaccinations against N. meningitidis , S. pneumoniae and H. influenzae
prior to first LNP023 dosing. 
Commercially Confidential Infor mation
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 35
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Efficacy  in terms of reversal of histopathologic changes will be assessed after the 12-week 
treatment period. Proteinuria and individual clinical response to various pharmacod ynamic 
markers as well as pharmacokinetics will be assessed over the 12-week treatment period 
(refer to Table 8-3and Table 8-4 for detailed sampling time).
In this context, proteinuria will be assessed by collecting 24-h urine andfirst morning void 
urine to assess thechange in and evolution of: UA and UP excretion, UACR and UPCR, 
creatinine clearance and hematuria. 
Safety  monitoring includes the following assessments for each visit during Treatment period s
 and alerts will be set up for abnormal values to be reported immediately to investigator and sponsor :
Renal function surveillance including serum creatinine, eGFR (using the CKD -EPI
formula), hematuria, 24- h UA, UACR and UPCR assessments (refer to Section 8.3)
Blood pressure (refer to Section 8.4.4.2 )

12-lead ECG (refer to Section 8.4.2)
Infection surveillance (refer to Section 10.2.3 )
Liver safety  (refer to Section 10.2.1)
Hematology  and blood chemistry  parameters (refer to Section 8.4.1)
Vital signs (refer to Section 8.4.4)
Physical examination (refer to Section 8.4.7)
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 36
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
AEs and SAEs recording (refer to Section 10)
4 Rationale
4.1 Rationale for study  design
The study has two separate cohorts (A and B), since two distinct C3G patient populations are 
investigated.
In both Cohorts the study  treatment period starts with a within -patient dose-escalation 
portion 
of 4 weeks, to establish a Dose -PD and PK-PD relationship for LNP023 and to assess the 
relationship between LNP023 PD -effect and efficacy . To this end patients will be treated with 
increasing doses of LNP 023, 
A PK assessment will be done on the last 
day of the respective dose level. The key  biomarkers that will be assessed in this study  are C3, 
and Bb as they have been shown to be dysregulated in patients with C3G 
(Nester andSmith 2016; Zhang et al 2014 ). Other biomarkers may  be investigated.
Treatment period  following the dose-escalatio n portion, includes a
period for both Cohorts. In Cohort A, this will be used to assess the primary  objective of efficacy 
with LNP023 (200 mg dose ), i.e., to reduce proteinuria in the specific C3G non-
transplanted population . This endpoint was chosen since urinary  protein levels are known to 
correlate with kidney function/inflammation and therefore are expected to provide an objective 
means to measure drug effect. Importantly , Cohort B will also assess histopathologic 
improve ment in renal biopsies. Biopsy  response will be investigated in transplanted patients, 
due to higher availability  of preexisting baseline biopsies (biopsies taken within 3 months 
before the baseline visit) and the higher acceptance of kidney  biopsies at the end of treatment 
in this particular population. 
The underl ying pathophy siology  causing C3G is uncontrolled activation of the AP of the 
complement system (Medjeral -Thomas et
al2014 )manifesting as two major subgroups that are 
recognized based on electron microscopic appearance as either C3 glomerulonephritis, or dense 
deposit disease (Sethi et al 2017). Treatment options for these disorders are quite limited, and 
disease progression often leads to end-stage renal disea se requiring renal replacement therap y 
and/or kidney  transplantation. To note, both diagnoses recur in most patients after 
transplantation, leading to graft loss in up to half of affected cases. In the largest reported series 
to date with C3GN who underwen t renal transplantation from the Ma yo Clinic, 68% developed 
recurrent C3GN. The median time to recurrence was 28 months but starting as early  as 9 day s 
post transplant, highlighting the high unmet medical need especially  for this 
population 
receiving an allograft for C3G related end-stage renal disease (Braun et al 2005; 
Commercially Confidential Information
Commercially Confidential Information
CCI
CCI
Commercially Confidential Information
Novartis Confidential Page 37
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Zand et al 2014 ). In order to create evidence that Factor B inhibition ameliorates C3G in both, 
native -as well as transplanted kidney s, Cohort A and B will be conducted concurrently . Trial 
experience with LNP023 to date indicate that treatment with LNP023 was well tolerated; as 
single agent treatment (ongoing study  CLNP023X2203 in IgA nephropathy ), or as add-on 
therap y for PNH patients with active hemol ysis despite C5 complement inhibition with 
eculizumab (CLNP023X2201, ongoing). Studies with other complement inhibitors such as 
eculizumab further support the safety  of the proposed approach demonstrating that broader 
complement inhibition (anti C5) also in immunosuppressed patients post kidney  transplantation 
was well tolerated (e.g., studies Stegall et al 2011; Bentall et al2014 ; [STUDY_ID_REMOVED]; 
[STUDY_ID_REMOVED]; [STUDY_ID_REMOVED]; [STUDY_ID_REMOVED] in CT.gov website).
Since the intrinsic turnover rate of C3andBb is known to be in the range of a few minutes to 
hours (Kirschfink andMollnes 2003), near complete stead y state conditions are likely to be 
achieved within 1 week of starting each new dose level. Thus measurements of PD effect at the 
end of each one week dosing period are considered to provide reliable data for assessment of 
PK/PD relationship.
In aggregate, concomitant determination of PK, 
PD, and Dose -PD relation at different dose 
levels is intended to provide data to support dose selection for subsequent confirmatory  studies. 
A conventional dose-ranging study  with different doses in separate treatment arms was not 
pursued due to the low prevalence of the disease.
In order to establish a Dose/PD relationship based on complement biomarkers, only C3G 
patients with reduced C3levels at baseline will be included into Cohort A. 
However due to higher acceptance of kidney  biopsies in 
this population we will seek to demonstrate histologic improvement in this patient population 
in addition to improvement in UP and UA. Histologic evaluation of kidney  biopsies will focus 
on the pillars: C3 deposits, disease activity in C3G lesions and chronic C3G related changes in 
the kidney . Each of these pillars will be evaluated by scores that comprise different light-, 
fluorescence -and electron -microscopica l parameters. Collectivel y these parameters will allow 
to determine if blockade of Factor B is sufficient to reduce C3 deposition and disease activity . 
Reversal of chronic changes is not expected within the timeframe of the proposed study .
Three different types of urine collection will be used: first morning void urine collection, 24 -h 
urine collection, and spot midstream urine collection. The first method will be used for inclusion 
criteria assessment and easy  monitoring, the second will be used during bas eline and treatment 
to evaluate the creatinine clearance, the third will be used for biomarker analysis, and safet y 
monitoring.
Patients in both Cohorts will be offered the possibility  to roll-over directl y in an extension study  
at the end of Treatment period
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 38
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.1.1 Rationale for choice of background therapy
LNP023 blocks FB and thereby  the AP, which is important for the defense against microbes. 
Thus, patients with mutations of FB are generally healthy, but have impaired resistance against 
selected bacterial infections (Slade et al 2013 ). Complement is particularly  important for the 
destruction of encapsulated bacteria such as N. meningitidis , S.pneumoniae and H.influenzae .
With the vaccination described above, the risk for serious infection during LNP023 treatment 
is considered to be very low. Relevant vaccinations should be performed prior to initiation of 
LNP023. 
. Further details and the vaccination strategy are outlined in Section 8.4.9.
4.2 Rationale for dose/regimen and duration of treatment
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 39
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs
Not applicable.
Commercially Confidential Information
Novartis Confidential Page 40
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.4 Purpose and timing of interim analy ses/design adaptations
4.5 Risks and benefits
LNP023 has not been previously  administered with therapeutic intent to patients with C3G. 
Therefore, no statement can be made at this time on the actual clinical benefits of LNP023 in 
this patient population. However, given the mechanism of action of LNP023 targeting the 
complement system as discussed in the background (Section 1.1), there is good rationale to 
believe that a therapeutic response can be achieved with the compound in patients with C3G.
Assuming a positive benefit -
risk assessment (i.e., a clinically  meaningful reduction in urinary 
protein excretion, and/or improvement in histology) it has been agreed with Health Authorities 
to offer CLNP023X2202 patients roll-over into the exte nsion study  CLNP023B12001B if the 
Investigator deems it to be clinicall y beneficial for the patient.
The risk to subjects in this trial may be minimized by compliance with the eligibility  criteria 
and study  procedures, as well as close clinical monitoring during the study  and stopping rules. 
Guidance for the investigators is included in the IB .
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study , and a gree that in order 
to participate in the study they must adhere to the contraception requirements outlined in the 
exclusion criteria. I f there is any  question that the subject will not reliably  comply , they  should 
not be entered or continue in the study .
There may be unknown risks of L NP023 which may  be serious.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 41
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.5.1 Blood sample volume
If patient will complete only Treatment period : approximately 670mL of blood is planned to 
be collected during Screening period, Treatment period  and the follow -up period (i.e.,over a 
period up to about 38 weeks from each subject from screening until EOS) from both Cohorts . 
Additional samples may  be required for safet y monitoring.
The timing of blood sample collections is outlined in the Assessment schedule (refer to 
Section 8).
A summary  blood log is provided in the Site Operations Manual. Instructions for all sample 
collection, processing, storage and shipment information are 
also available in the SOM and 
Central Laboratory Manual.
Refer to Section 8.5.3.6 regarding the potential use of residual samples.
4.5.2 Potential risks
The potential risk of LNP023 can only be assessed indirectly b y analyzing the pharmacological 
profile, preclinical safety studies and clinical studies.
4.5.3 Risk for infections
In this stud y, LNP023 is used to block the complement AP. Patients with mutations of factor B 
are generally  perfectl y healthy , but have impaired resistance against bacterial infections. 
Ofparticular concern are rare, but serious, meningococcal or pneumococcal infections. In the 
general population the annual incidence of invasive infections with Neisseria meningitidis is 
between 0.1-2.0 cases per 100,000 with great variation between regions (Sridhar et al2015). 
For infections with Streptococcus pneumoniae , the annual risk is 35 cases per 100,000 for 
individuals <2 or >65 years of age, while it is 4 cases per 100,000 in individuals between 18 
and 35 years of age (Alanee et al 2007). The current risk for invasive infections with 
Hemophilus influenzae is 1.6 per 100,000 in the US ( MacNeil et
al2011 ).
Vaccination is predicted to be an 
effective mitigation strategy  to reduce the risk for individuals treated with LNP023.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 42
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
After a single injection of meningococcal vaccine, high titers are achieved after two weeks, but 
in most studies data on titers at Day 28 are reported (Gossger et al 2012, Keyserling et al2005). 
Similar effects are seen with the pneumococcal vaccines McFetridge et al 2015, 
Bryant et
al2015). Vaccinations should be performed prior to initiation of LNP023. 
During the two -month Screening period , vaccination wil l be done according to local regulation 
and practice prior totreatment to effectivel y increase the serological titers and reduce the risk 
for the individual in the unlikely  event of bacterial infection with N.meningitidis , 
S.pneumoniae or H. influenzae . The vaccines and the vaccination procedures recommended
vary between countries.
Patients must receive vaccinations against N. meningitidis , S. pneumoniae and H. influenzae
prior to first LNP023 dosing. 
4.5.4 Risk for testis tubular degeneration
Notably , no obvious fertility issue was observed in the complement FB knockout mouse model 
(Matsumoto 1999) or patients with genetic mutations in the complement AP (Skattum et al2011).
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 43
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.5.6 Non- clinical safety  findings of undetermined relevance
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 44
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
4.5.7 Risk mitigation strategy
Patients will return to the clinic on a regular basis. During these visits safet y, tolerability, 
efficacy  and PK/PD data will be collected. Standard safet y assessments will include vital signs, 
physical examinations, ECG, clini cal laboratory evaluations (hematology, blood chemistry and 
urinaly sis), and AEs as outlined in the Assessment schedule (Table 8-1and Table 8-3). 
Inaddition to standard clinical laboratory  assessme nts, subjects will be monitored regularl y for 
signs and symptoms of infections, inflammation, and hematologic and renal function as outlined 
below. Patients will be informed to report any symptoms to the clinical staff to assure proper 
assessment and so that care can be administered in a timely  manner.
In agreement with the primary  and secondary  objectives, measurement of UPCR and UACR, 
24-h urine excretion of albumin and protein will be made, and changes in renal function will be
assessed via serum creatin ine and estimated glomerular filtration rate (eGFR, Chronic Kidney
Disease -Improved Prediction Equations (CKD -EPI)).
A priori defined stopping criteria and guideline s (Section
9.1.4) in addition to the clinical 
opinion of the I nvestigator will be used to protect individual patient safety  during the trial.
Finally , key  safet y data will be reviewed b y the Sponsor on an ongoing basis.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 45
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
5 Population
As direct renal clearance has been shown to be a significant but not a predominant clearance 
pathway , this trial may  enroll patients with mild -to-moderate renal impairment.
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following criteria:
Population for Cohort A
Approximately  15 C3G patients with native kidneys and with reduced serum C3 levels (male or 
female) will be enrolled in Cohort A to ensure that 12 patients complete the study  in this cohort.
1.Written i nformed consent must be obtained before any assessment is performed.
2. Male and female patients 18 years old or older atscreening visit
3.Patients must have C3G as confirmed b y renal biopsy  within twelve months prior to
enrollment (confirmation by  the Invest igator is required).
4.C3G patients with reduced C3 at screening
5. Able to communicate well with the investigator, to understand and comply with the
requirements of the study.
6.At screening and baseline visits, patients must weigh at least 35 kg to participate in the
study ,
7. V ital signs should be within the following ranges :
body  temperature between 35.0- 37.5 °C sy stolic blood pressure, 80 -170 mm Hg diastolic
blood pressure, 50 -105 mm Hg pulse rate, 45 
- 100 bpm
8.Estimated GFR (using the CKD -EPI formula) ≥30 mL /min per 1.73 m2for patients on a
maximum recommended or maximum tolerat ed dose of an angiotensin converting enzy me
inhibitor (ACEI ) or angiotensin receptor blocker (ARB).
9.UPCR ≥ 100 mg/mmol sampled from first morning void (or≥ 1 g/24h total urinary  protein
excretion from a 24h collection during run- in) at run-in (Visit 20) o r at baseline (Visit 30).
11.Prior to Day  1, all patients must have been on supportive care including a maximally
tolerated dose of ACEi or ARB for at least 30 days.
12.
14.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 46
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
15
Population for Cohort B
Approximately  12 C3G kidney  transplanted patients (male or female) with C3G recurrence will 
be enrolled in Cohort B to ensure that at least 10 complete the study  in this cohort.
16.Written informed consent must be obtained before any  assessment is performed.
17. Male and female patients  18 yearsold or older at scr eening visit
18.Patients must have C3G recurrence after transplantation as confirmed b y renal biopsy  after
transplantation within twelve months prior to enrollment (confirmation by  the Investigator
is required).
19. Able to communicate well with the investigator, to understand and comply with the
requirements of the study.
20. At screening and baseline visits, patients must weigh at least 35 kg to participate in the
study ,
21. Vital signs should be within the following ranges:
body  temperature between 35.0- 37.5 °C sy stolic blood pressure, 80 -170 mm Hg diastolic
blood pressure, 50 -105 mm Hg pulse rate, 45 - 100 bpm
22.
23.Normal or elevated u rinary protein excretion at screening or  at baseline (Visit 30).
25.
26. 
27.No histological/laboratory /clinical signs of allorejection
28.If applicable, induction treatment after allotransplantation needs to be completed > 30 day s
before screening visit .
29.Transplantation of a kidney  allograft >90 day s before screening visit
30.Patients need to be on a stable dose of immunsuppressive regimen
prior to Day 1. Any approved treatments are allowed for this purpose (if not prohibited as
per protocol) .
32.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
CCI
Commercially Confidential Information
Novartis Confidential Page 47
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
33.
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
Population for Cohort A
Approximately  15 C3G patients with native kidneys and with reduced serum C3 levels (male 
or female) will be enrolled in Cohort A to ensure that 12 patients complete the study  in this 
cohort.
1.
2. Use of other investigational drugs at the time of enrollment, or within 5 half- lives, or
within 30 day sof screening , whichever is longer; or longer if required b y local regulations
3.A history of clinically  significant ECG abnormalities,
4.Known famil y history or known presence of long QT syndrome or Torsades de Pointes
5.Use of agents known to prolong the QT interval unless they  can be permanently
discontinued for the duration of the study
6.
7.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female
after conception and until the termination of gestation, confirmed by  a positive hCG
laboratory  test.
8.Women of child- bearing potential, defined as all women phy siologica lly capable of
becoming pregnant, unless they  are using highly  effective methods of contraception
during dosing and for 1 week after stopping of investigational drug.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 48
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 49
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
12.History  of immunodeficiency  diseases, or a positive HIV test result at screening visit.
13.
14.Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV) at screening visit .
15.
16. Patients who cannot receive vaccinations against N. meningitidis , S. pneumoniae , or
H.influenzae .
17.
18.
19.
42.
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible subjects
Population for Cohort B
Approximately  12 C3G kidney  transplanted patients (male or female) with C3G recurrence will 
be enrolled in Cohort B to ensure that at least 10 complete the study  in this cohort.
20. Use of other investigational drugs at the time of enrollment, or within 5 half- lives of
enrollment, or within 30 day s, whichever is longer; or lo nger if required b y local
regulations.
21.A history
 of clinically  significant ECG abnormalities,
22.Known famil y history  or known presence of long QT sy ndrome or Torsades de Pointes
23.Use of agents known to prolong the QT interval unless they  can be permanently
discontinued for the duration of the study
24.
25.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female
after conception and until the termination of gestation, confirmed by  a positive hCG
laboratory  test.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 50
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
26.Women of child- bearing potential, defined as all women physiologicall y capable of
becoming pregnant, unless they  are using highly  effecti ve methods of contraception
during dosing and for 1 week after stopping of investigational drug.
Commercially Confidential Information
Novartis Confidential Page 51
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
30.History  of immunodeficiency  diseases, or a positive HIV test result at screening visit .
31.
32.Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV) at screening visit
33.
34. Patients who cannot receive vaccinations against N. meningitidis , S. pneumoniae , or
H.influenzae
35.
36.
37.
38.
39.
40.
41.
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible subjects
6 Treatment
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 52
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
6.1 Stud y treatment
Details on the requirements for storage and management of study treatment, and instructions to 
be followed for subject numbering, prescribing/dispensing and taking study  treatment are 
outlined in the Site Operations Manual (SOM).
6.1.1 Investigational and control drugs
The investigational drug, LNP023 as 5 mg, 25 mg, 100 mg capsules will be prepared by 
Novartis and supplied to investigator sites as open label subject packs.
Table 6-1 Overview of study  medication
Investigational 
DrugPharmaceutical 
Dosage FormRoute of 
AdministrationPackaging Sponsor
LNP023 5 mg Capsules Oral use Open label 
subject packs; 
bottlesSponsor global
LNP023 25 mg Capsules Oral use Open label 
subject packs; 
bottlesSponsor global
LNP023 100 mg Capsules Oral use Open label 
subject packs; 
bottlesSponsor global
6.1.1.1 Bio-batch retention samples
Not applicable for this study .
6.1.2 Additional study treatments
No additional treatment bey ond investigational drugs are included in this trial.
6.1.3 Treatment arms/group
This is an open label study  where approximately  15 patients enrolled into Cohort A and 
approximately  12patients into Cohort B will be treated for up to 14 weeks 
 with LNP023 :
6.2 Other treatment(s)
Not applicable.
 CCI
CCI
Commercially Confidential Information
Novartis Confidential Page 53
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
6.2.1 Concomitant therapy
The investigator must instruct the subject to notify  the study  site about any new medications 
he/she takes after the subject was enrolled into the study .
All medications, procedures and significant non -drug therapies (including physical therap y and  
blood trans fusions) administered after the subject was enrolled into the study must be recorded 
in the specific CRF page.
Patients must receive vaccinations against N. meningitidis , S. pneumoniae and H. influenzae
prior to first LNP023 dosing. 
Medication entries should be specific to trade name, the single dose and unit, the frequency  and 
route of administration, the start and d iscontinuation date and the reason for therap y.
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt the investigator should contact the Sponsor medical monitor before 
enrolling a patient or allowing a new medication to be started. If the patient is alread y enrolled, 
contact the Sponsor to determine if the patient should continue participation in the study .
6.2.1.1 Permitted concomitant therapy  requiring caution and/or action
 list of drug to be used with 
caution will be provided to the I nvestigators.
6.2.2 Prohibited medication
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 54
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
Use of the treatments display ed in the table below is NOT allowed in patients enrolled in 
Cohort A and Cohort B .
6.2.3 Rescue medication
Not applicable.
6.2.4 Restriction for study  subjects
There are no specific restrictions
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 55
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
6.2.4.1 Dietary  restrictions and smoking
There are no specific dietary  or smoking restrictions.
6.2.4.2 Other restrictions
Not applicable. 
6.3 Subject numbering, treatment assignment, randomization
6.3.1 Subject numbering
The subject number assigned to a subject at screening remains the unique identifier for the 
subject throughout the study . For information on subject numbering, please see ‘Subject 
numbering’ section in the Site Operations Manual.
6.3.2 Treatment assignment, randomization
This is an open label study, no randomization to be performed.
6.4 Treatment blinding
Treatment will be open to subjects, investigator staff, persons performing the assessments, and 
the CTT.
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions are not permitted
during Treatment period 
6.6 Additio nal treatment guidance
6.6.1 Treatment compliance
Pharmacokinetic parameters (measures of treatment exposure) will be determined in all subjects 
treated with LNP023, as detailed in Section
8.5.2.
The investigator must promote compliance by instructing the subject 
to take the study  treatment 
exactly  as prescribed and by stating that compliance is necessary  for the subject’s safet y and 
the validity  of the study . The subject must also be instructed to contact the investigator if he/she 
is unable for an y reason to take the study  treatment as prescribed .
Compliance will be assessed by  the Investigator and/or study  personnel at each visit using pill 
counts and information provided by the subject in the diaries. This information should be 
captured in the source document at each visit. All study treatment dispensed and returned must 
be recorded in the Drug Accountability  Log.
Commercially Confidential Information
Novartis Confidential Page 56
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
6.6.2 Recommended treatment of adverse events
At present, there is insufficient information to provide specific recomme ndations regardin g 
treatment of AEs. There is no treatment that can reverse the activity  of LNP023. LNP023 is a 
small molecule with a half-life of 12 hours. Potential AEs should therefore be treated 
symptomaticall y at the discretion of the Investigator. Medication used to treat AEs must be 
recorded on the specific CRF page. 
6.6.3 Emergency  breaking of assigned treatment code
Not applicable since this is an open label stud y.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packagin g as described under the 
investigational and control drugs section (refer to Section 6.1.1).
LNP023 will be administered to the subject via the following route of administration: oral.  
See the SOM for further details.
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnessed, where required 
by law or regulation), I RB/IEC -approved informed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subje ct must be informed about the study  to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
personall y signing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents.
Sponsor will provide to investigators in a separat e document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
Investigator must be agreed by  Sponsor before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the IB. This information will be included in the subject informed consent and should 
be discussed with the subject during the study  as needed. Any new information regarding the 
safet y profile of the investigational drug that is identified between IB updates will be 
communicated as appropriate, for example, via an investigator notification or an aggregate 
Commercially Confidential Information
Novartis Confidential Page 57
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
safet y finding. New information might require an update to the informed consent and then must 
be discussed with the subject.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
A copy of the approved version of all consent forms must be provided to Sponsor after IR B/IEC 
approval.
Refer to the Site Operations Manual for a complete list of I CFs included in this study .
Commercially Confidential Information
Novartis Confidential Page 58
Amended Protocol Version v03 (Clean ) Protocol No. CLNP023X2202
8 Visit schedule and assessments
Assessment schedule lists all of the assessments and indicates with an “X”, the visits when they 
are performed. All data obtained from these assessments must be supported in the subject’s 
source documentation.
Subjects should be seen for all visits/assessments as outlined in the assessment schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontin uation. Subjects who prematurely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adverse event and concomitant medications recorded on the CRF.
Novartis Confidential Page 59
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Table 8-1 Assessment Schedule, Cohort A
Treatment Period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
Informed consent X
Demography X
Inclusion / Exclusion 
criteriaX X X3
Medical 
history/current 
medical conditionsX X X
Prior m edications X
Physical 
ExaminationS S S
Hepatitis and HIV 
screenS
Tuberculosis status X
Pregnancy and 
assessments of 
fertility4S S S S S
X5X6X6
Renal biopsy X7,8X2
S S
X
X X X X
CCICCI CCI CCI CCI
CCI
CCI
CCI
CCI
Novartis Confidential Page 60
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment Period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
Vital Sig ns7,9,11See table below
ECG evaluation10X X X X28X X X X X28X X
Hematology7,11X X X X X X X X X X
Blood chemistry7,11, 12X X X X X X X X X X
Urinalysis7,11X X X X X X X X X X
Vaccination13,14X X15
Study drug 
dispensationX X27X27X27X X
24-hours urine
collection16X31
X X X
Spot urine collection 
-First Morning Void7 X17X17X17X17X17X17X17
Spot urine collection 
- Mid Stream18,19 X X X X X X X X
X X X X X X X X X X
eGFR X X X X X X X X X X
PK sample collection See table below
C3 See table below
Complement 
pathway biomarkers 
in plasma21See table below
CCI CCI CCI CCI
CCI
CCI
CCICCI
Novartis Confidential Page 61
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment Period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
Complement 
pathway biomarkers 
in serum23See table below
X X X X X X X X
Subject domiciled X X X
Subject discharged X X
Adve rse Events / 
Serious Adverse 
Events24X
Concomitant 
medications / 
therapiesX
X
Study completion 
information
Safety Follow up Call
CCI CCI CCI CCI
CCI
CCI
Novartis Confidential Page 62
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period Safety  Follow -up period
Period
Visit Name Follow -up EOS Post  study   safety   contact
Visit Numbers1190 195 200 210 230 240 250 1999
Days85 16992 or 
17699 or 
183113 or 197 127 or 211 155 or 239 183 or 
267 Last treatment  + 30 day s
Time (post-
dose)- - - - - - - -
Informed 
consent
Demography
Inclusion / 
Exclusion 
criteria
Medical 
history/current 
medical 
conditions
Prior 
medications
Physical 
ExaminationS S
Hepatitis and 
HIV screen
CCI CCICCI
CCI
Novartis Confidential Page 63
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period Safety  Follow -up period
Period
Visit Name Follow -up EOS Post  study   safety   contact
Visit Numbers1190 195 200 210 230 240 250 1999
Days85 16992 or 
17699 or 
183113 or 197 127 or 211 155 or 239 183 or 
267 Last treatment  + 30 day s
Time (post-
dose)- - - - - - - -
Tuberculosis 
status
Pregnancy and 
assessments of 
fertility4S S S
Renal biopsy
X 
Vital Signs7,9,11See table below
ECG 
evaluation10 X X X X X
Hematology7,11X X X X X X
Blood 
chemistry7,11,12 X X X X X X
CCI CCICCI
CCI
CCI
CCI
CCI
Novartis Confidential Page 64
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
PeriodSafety  Follow -up period
Period
Visit Name Follow -up EOS Post  study   safety   contact
Visit Numbers1190 195 200 210 230 240 250 1999
Days85 16992 or 
17699 or 
183113 or 197 127 or 211 155 or 239 183 or 
267 Last treatment  + 30 day s
Time (post-
dose)- - - - - - - -
Urinalysis7,11X X X X X X
Vaccination13,14
Study drug 
dispensationX30X27X27
24-hours urine
collection16 X
Spot urine 
collection -First 
Morning Void7X17X17X17X17X17X17X17
Spot urine 
collection -Mid 
Stream18,19X X X X X
X X X X X X
eGFR X X X X X X
PK sample 
collectionSee table below
C3 See table below
CCI CCICCI
CCI
Novartis Confidential Page 65
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period Safety  Follow -up period
Period
Visit Name Follow -up EOS Post  study   safety   contact
Visit Numbers1190 195 200 210 230 240 250 1999
Days85 16992 or 
17699 or 
183113 or 197 127 or 211 155 or 239 183 or 
267 Last treatment  + 30 day s
Time (post-
dose)- - - - - - - -
Complement 
pathway 
biomarkers in 
plasma21See table below
Complement 
pathway 
biomarkers in 
serum23See table below
X X
Subject 
domiciledX
Subject 
dischargedX
CCI CCICCI
CCI
CCI
Novartis Confidential Page 66
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period Safety  Follow -up period
Period
Visit Name Follow -up EOS Post  study   safety   contact
Visit Numbers1190 195 200 210 230 240 250 1999
Days85 16992 or 
17699 or 
183113 or 197 127 or 211 155 or 239 183 or 
267 Last treatment  + 30 day s
Time (post-
dose)- - - - - - - -
Adverse Events 
/ Serious 
Adverse 
Events24X
Concomitant 
medications / 
therapiesX
X
Study 
completion 
informationX
Safety Follow up 
CallS
CCI CCICCI
CCI
Novartis Confidential Page 67
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
XAssessment to be recorded in the clinical database or received electronically from a vendor
SAssessment to be recorded in the source documentation only
1Visit structure given for internal programming purpose only
3Verify again the Inclusion Criteria #5,6,7, 11,12 and the Exclusion Criteria # 3, 5, 7, 8, 9, 10.
4Serum pregnancy test required at screening and at end of treatment. Urine pregnancy test at further time points.
7During treatment, assessment is performed pre morning dose
8Renal biopsy has to be performed any time during screen ing period in case the most recent bioptic material is older than 12 months.
9Includes pulse rate, blood pressure and temperature
10Triplicate ECGs at all visits 
11Including infection surveillance
12Including liver safety monitoring (ALT, AST, ALP, TB L, PT/INR, γGT levels assessment)
13If not previously vaccinated, patients will receive vaccination against Neisseria meningitidis , Streptococcus pneumoniae , and Haemophilus influenz aeaccording to 
local guidelines
16Includes UACR and UPCR, 24h urine excretion of albumin and protein, (PK only at Visit 140)
19During treatment, collection should be performed possibly at the same time, i.e. about half an hour after morning dose at sit e, except at Visit 18 0, where collection 
should be performed before starting the 24h urine collection, independently by the dose intake.
21Including, but not limited to, Factor Bb, and sC5b-9
24All AEs will be collected from Informed Consent until the End Of Study visit, all SAEs will be collected until 30 days after the End Of Study visit
27New dose capsules to be dispensed , see SOM for details
28To be performed pre-dose and 1h post dose
31It may be performed for screening purposes.
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information

Novartis Confidential Page 68
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Table 8-2 Details for highly  repetitive assessments , Cohort A
Commercially Confidential Information
Novartis Confidential Page 69
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 70
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 71
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Table 8-3 Assessment Schedule, Cohort B
Treatment period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
Informed consent X
X
Demography X
Inclusion / Exclusion 
criteriaX X X3
Medical
history/current 
medical conditionsX X X
Prior m edications X
Physical Examination S S S
Hepatitis and HIV 
screenS
Tuberculosis status X
Pregnancy and 
assessments of 
fertility4S S S S S
X5X6X6
Renal biopsy X7X
S S
X
X X X X
Vital Sig ns8,9,11See table below
CCI CCI CCI CCI
CCI
CCI
CCI
CCI
CCI
Novartis Confidential Page 72
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
ECG evaluation10X X X X29X X X X X29X X
Hematology8,11X X X X X X X X X X
Blood chemistry8,11, 12X X X X X X X X X X
Urinalysis8,11X X X X X X X X X X
Vaccination13,14X X15
Study drug 
dispensationX X28X28X28X X
24-hours urine
collection16X32
X X17X17
Spot urine collection 
-First Morning Void8 X18X18X18X18X18X18X18
Spot urine collection 
- Mid Stream19,20 X17X X X X17X17X17X17
X X X X X X X X X X
eGFR X X X X X X X X X X
PK sample collection See table below
C3 See table below
Complement 
pathway biomarkers 
in plasma22See table below
Complement 
pathway biomarkers 
in serum23See table below
CCI CCI CCI CCI
CCI
Novartis Confidential Page 73
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment period
Period Screening
Visit Name Screening Run-in Baseline
Visit Numbers11 20 30 40 100 110 120 130 140 150 160 170 180
Days-90 to -30 -89 to -40 -60 to -30-30-1 1 7 14 21 28 29 36 64 84
Time (post-dose) - - - - - Pre-dose Pre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose 0.5h 8hPre-dose - - - -
X X X X X X X X
Subjects domiciled X X X
Subject discharged X X
X
Adverse Events / 
Serious Adverse 
Events27X
Concomitant 
medications / 
therapiesX
Study completion 
information
Safety Follow up Call
CCI CCI CCI CCI
CCI
CCICCI
CCI
Novartis Confidential Page 74
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
Informed 
consent
Demography
Inclusion / 
Exclusion 
criteria
Medical 
history/current 
medical 
conditions
Prior 
medications
Physical 
ExaminationS S
Hepatitis and 
HIV screen
CCI CCI
CCI
Novartis Confidential Page 75
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
Tuberculosis 
status
Pregnancy and 
assessments 
of fertility4S S S
Renal biopsy
X
Vital Signs8,9,11See table below
ECG 
evaluation8,10 X X X X X
CCI CCI
CCI
CCI
CCI
CCI
Novartis Confidential Page 76
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
Hematology8,11X X X X X X
Blood 
chemistry8,11,12 X X X X X X
Urinalysis8,11X X X X X X
Vaccination13,14
Study drug 
dispensationX31X28X 28
24-hours urine
collection16 X17
Spot urine 
collection -
First Morning 
Void8X X18X18X18X18X18X18
Spot urine 
collection -Mid 
Stream19,20X X17X17X17X17
X X X X X X
CCI CCI
CCI
Novartis Confidential Page 77
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
eGFR X X X X X X
PK sample 
collectionSee table below
C3 See table below
Complement 
pathway 
biomarkers in 
plasma22See table below
Complement 
pathway 
biomarkers in 
serum23See table below
X X
Subjects 
domiciledX
CCI CCI
CCI
CCI
Novartis Confidential Page 78
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
Subject 
dischargedX
X
Adverse 
Events / 
Serious 
Adverse 
Events27X
Concomitant 
medications / 
therapiesX
Study 
completion 
informationX
Safety Follow 
up CallS
CCI CCI
CCI
Novartis Confidential Page 79
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
XAssessment to be recorded in the clinical database or received electronically from a vendor
SAssessment to be recorded in the source documentation only
1Visit structure given for internal programming purpose only
3Verify again Inclusion Criteria # 19, 20, 21, 25, 26 and Exclusion Criteria # 21, 23, 25, 26, 27, 28.
4Serum pregnancy t est required at screening and at end of treatment. Urine pregnancy test at further time points.
7Renal biopsy has to be performed any time during the screening period, in case the most recent bioptic material is older than 3 months.
8During treatment period, the assessment is performed pre morning dose
9Includes pulse rate, blood press ure and temperature
10Triplicate ECGs at all visits 
11Including infection surveillance
12Including liver safety monitoring (ALT, AST, ALP, TBL, PT/INR, γGT levels assessment)
13If not previously vaccinated, patients will receive vaccination against Ne isseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae 
according to local guidelines
16Includes UACR and UPCR, 24h urine excretion of albumin and protein, (PK only at Visit 140 )
17To be performed at site
20During treatment, collection should be performed possibly at the same time, i.e. about half an hour after morning dose at sit e, except at Visit 180 
where collection should be performed before starting 24h urine collection , independently by the dose intake
27All AEs will be collected from Informed Consent until the End Of Study visit, all SAE s will be collected until 30 days after the End Of Study visit
28 New dose capsules to be dispensed, see SOM for details
29 To be performed pre-dose and 1h post dose
32It may be performed for screening purposes
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confidential Page 80
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Treatment 
Period  Safety  Follow -up period
PeriodDosing tapering 
periodSafety  follow -up -
Visit Name Follow -up EOS Post  study   safety   contact
Visit 
Numbers1190195200 210 230 240 250 1999
Days 85169 92 or
17699 or 
183113  or
197127 or 
211155 or 239 183 or
267Last treatment  + 30 day s
Time (post-
dose)- - - - - - -
CCI CCI
Novartis Confidential Page 81
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Table 8-4 Details for highly  repetitive assessments , Cohort B
Commercially Confidential Information
Novartis Confidential Page 82
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confidential Page 83
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confide ntial Page 84
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
8.1 Screening
It is permissible to re -screen a subject if s/he fails prior toscreening; however, each case must 
be discussed and agreed with the Sponsor on a case- by-case basis.
In the case where a safet y laboratory  assessment at screening and/or initial baseline is more than 
10% outside of the range specified in the exclusion criteria, the assessment may be repeated 
once prior to randomiz ation. If the repeat value remains outside of the specified ranges, the 
subject must be excluded from the study .
Information on what data must be collected for screening failures and further information on 
re-screening is outlined in the Site Operations Ma nual.
8.1.1 Information to be collected on screening failures
Refer to SOM for details on information to be collected for screening failures.
8.2 Subject demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects. 
Relevant medical history/current medical conditions data will also be collected until signature 
of informed consent. Details are outlined in the Site Operations Manual. Investigators have the 
discretion to record abnormal test findings on the medical history  CRF, if in their judgment, the 
test abnormality  occurred prior to the informed consent signature.
8.2.1 Hepatitis screen, HIV screen
All subjects will be screened for HIV, Hepatitis B and C. See the Site Operations Manual for 
details.
8.2.2 Tuberculosis status
Determination of tuberculosis status will be required before administration of study  treatment. 
Any significant findings will be recorded in the “Relevant medical history /Current medical 
conditions” section of the eCRF.
The quantiferon test for tuberculosis status will be analy zed by the Central laboratory . 
Details on the collection, processing and shipment of samples and reporting of the results by 
the Central laboratory  are provided in the laboratory  manual.
8.2.4 Renal Biopsies for screening evaluation
For kidney  native patients in Cohort A of the study , the diagnosis of C3G must be based on a 
renal biopsy  not older than 12 months. In case of an older biopsy  patients will be asked to 
perform a new renal biopsy  during the run-in period to confirm eligilibity . More details are 
outlined in the Site Operations Manual.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 85
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
For patients transplanted, C3G diagnosis should be supported by specific documentation. 
More details on biopsies collection for Cohort B patients are reported in Section 8.3.3 under 
Efficacy  section.
8.3 Efficacy /Pharmacody namics
Efficacy  /  Pharmacod ynamic samples will be collected at the time points defined in the 
Assessment schedule (refer to Table 8-1and Table 8-3). Follow instructions outlined in the Site 
Operations Manual regarding sample collection, numbering, proce
ssing and shipment.
Pharmacod ynamic (PD) samples will be obtained and evaluated in all subjects at all dose levels.
8.3.1 Appropriateness of efficacy  assessments
Primary  endpoint Cohort A: Reduction in proteinuria from baseline at Week 12.
This endpoint was chosen since the urinary  protein level is known to correlate well to kidney
function/inflammation, is a parameter closely  related to disease progression and is expected
to provide a sensitive and objective means to measure drug effect in comparison to baseline.
Proteinuria will be assessed by collecting urine for 24 hours and measuring the protein to
creatinine concentration ratio (UPCR). The total duration of the treatment period is
considered sufficient to see relevant treatment effect on the selected primary endpoint based
on literature ( Fellström etal2017) and guidelines ( KDIGO 2012 ).
Primary  endpoint Cohort B: Change from baseline in C3 Deposit Score (based on
immunofluorescence microscopy ). This endpoint will be assessed by  a score comprising
reduction in C3 deposition assessed b y immune fluoresc ence staining. This endpoint was
chosen since renal C3 deposition is required to establish C3G diagnosis. Further C3
deposition is directly linked to C3G pathophy siology  and considered causal to renal
impairment.
Secondary  endpoints for Cohort A and B: Com plement biomarkers (e.g. Bb, C3 in serum)
to assess the pharmacod
ynamic effect at different doses of LNP023. For C3G, the
underly ing mechanism causing renal disease is dysregulation of complement AP C3- and
C5-
convertase. LNP023 is expected to block the d ysregulation and thereby  should
normalize compl ement biomarker levels in serum . Therefore, assessment of the effect of
LNP023 on complement biomarkers should identify doses that would be expected to be
efficacious for treatment of this disease. Bb and C3 a re biomarker s that accuratel y reflect
the level of complement AP activation. Complement biomarkers are therefore considered
to be sensitive and accurate estimates of target engagement
8.3.2 24-hours urine collection
Measurement includes UPCR and UACR, 24-h UP and 24-h UA, creatinine clearance, 
hematuria and PK (only during treatment period visits). Samples may also be used to assess
urine 
protein size profiles to explore kidney  damage.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 86
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Refer to SOM for more details.
8.3.3 Renal Biopsies for efficacy  evaluation
To assess histopathological changes in kidney  biopsies of patients transplanted in Cohort Bof 
the study , a renal biops y will be collected any tim e during run -in period as baseline, if the most 
recent biops y is older than 3 months. A renal biopsy  has to be collected at Week 12.  
8.3.4 Glomerular filtration rate
Estimated glomerular filtration rate (eGFR) is calculated appl ying the Chronic Kidney  Disease 
Epidemiology  Collaboration (CKD -EPI) equation) ( Leve yet
al2009).
GFR = 141 × min (S cr/κ, 1)α× max(S cr/κ, 1)-1.209× 0.993Age× 1.018 [if female] × 1.159 [if black]
where: Scris serum creatinine in 
mg/dL , κ is 0.7 for females and 0.9 for males, α is -0.329 for 
females and -0.411 for males, min indicates the minimum of S cr/κ or 1, and max indicates the 
maximum of S cr/κ or 1.
The equation does not require weight because the results are reported normalized to 1.73 m2
body  surface area, which is an accep ted average adult surface area.
8.3.5 Pharmacody namic Assessments
Pharmacod ynamic assessments are specified below, with the methods for assessment and 
recording specified in the SOM. Assessments will be performed/samples collected at the 
timepoints defined in the Assessment Schedule (refer to Table 8
-1and Table 8-3).
8.3.5.1 Renal Parameters
The pharmacod
ynamic effect of LNP023 is assessed anal ysing the following renal parameters:
UA, UACR, UP, UPCR, serum creatinine, creatinine clearance, eGFR, hematuria
Ratio to baseline of UPCR and UACR derived from 24- h urine collection
Commercially Confidential Information
Novartis Confide ntial Page 87
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
8.3.5.2 Complement pathway biomarkers
Soluble complement biomarkers in circulation and urine will be evaluated as potential 
pharmacod ynamics and mode -of-action markers. They  may  include, but are not be limited to:
Circulating fragment of factor B (Bb)
C3

8.3.6 First morning void urine collection
First morning void urine will be collected 
(refer to Table 8-1and Table 8-3).
Measurement includes UPCR and UACR, UP and UA, hematuria.
Refer to SOM for more details.
8.4 Safet y
Safety  assessments are specified below with the Assessment schedule (refer to Section 8) 
detailing when each assessment is to be performed.
For details on AE collection and reporting, refer to Section 10.1.
The methods for each assessment and data recording details are specified in the SOM.
8.4.1 Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of samples and reporting of results by  the central laboratory  are provided 
to Investigators in the Laboratory  Manual.
Clinically  significant abnormalities must be recorded on the relevant section of the medical 
history /Current medical conditions/AE CRF / e(CRF) page as appropriat e.
8.4.1.1 Blood Chemistry
Albumin, Alkaline phosphatase, ALT , AST , Gamma -glutam yl-
transferase (GGT), Lactate 
dehy drogenase (LDH), Bicarbonate, Calcium, Magnesium, Phosphorus, Chloride, Sodium, 
Potassium, Creatinine, Creatine kinase, Cystatin C (Cys C), Direct Bilirubin, Indirect Bilirubin, 
Total Bilirubin, Total Cholesterol, LDL -C, HDL -C, Trigl ycerides, Total Protein, Blood Urea 
Nitrogen (BUN) or Urea, Uric Acid, Amy lase, Lipase, Glucose, CK-MB, VLDL -C and non 
HDL -C, (hs)CRP.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 88
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
8.4.1.2 Hematology
Hemoglobin, hematocrit, red blood cell (RBC) count, white blood cell (WBC) 
count with differentials and platelet count will be measured. Coagulation testing including 
prothrombin time (PT) also reported as INR and activated partial thromboplastin time (aPTT) 
will be measured.
8.4.1.3 Urinaly sis and Urine Microscopy
Dipstick measurements for leucocy tes, protein, blood will be performed. Any positive result, 
atypical for a C3G patient, will require a sample to be sent for further microscopy  assessment 
of WBC, RBC and sediments. Results for both the positive dipstick parameters and the 
microscop y will be recorded in the appropriate eCRFs.
8.4.2 Electrocardiogram (ECG)
Full details of all procedures relating to the ECG collection and reporting are contained in the 
Site Operati ons Manual.
All ECGs are done as 12-lead triplicate ECGs. All ECG evaluations will be done by the 
Investigators.
PR interval, QRS duration, heart rate, RR interval, QT interval, QTc
The Fridericia QT correction formula (QTcF) must be used for clinical deci sions.
As applicable, 
QTcF and QTcB may be calculated in-house. Unless auto- calculated by the ECG 
machine, the investigator must calculate QTcF at the Screening and/or Baseline visit(s) (as 
applicable).
Clinically  significant abnormalities must be reported in the AE CRF.
8.4.3 Pregnancy  and assessments of fertility
Pregnancy  Testing
All pre -menopausal women who are not surgicall y sterile will have pregnancy  testing. See the 
Assessment schedule (Section 8), for timing of the protocol required pregnancy  testing in serum 
or urine; additional pregnancy  testing may be performed to meet local requirements*. A positive 
urine pregnancy  test requires 
immediate interruption of study  treatment until serum β-hCG is 
performed and found to be negative.
*Additional pregnancy  testing might be performed if requested per local requirements.
Refer to Section 10.1.4 for details on Reporting Pregnancy .
CCI
Novartis Confide ntial Page 89
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Assessments of Fertility
Refer to Section 5.2 for criteria to determine women that are not of child bearing potential.
Medical documentation of oophorectom y, hysterectomy , or tubal ligation must be retained as 
source documentation . Subsequent hormone level assessment to confirm the woman is not of 
child bearing potential must also be available as source documentation in the following cases:
surgical bilateral oophorectomy  without a hy sterectomy
reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile.
8.4.4 Vital Signs
8.4.4.1 Pulse Rate
Pulse r ate will be measured as per Assessment Schedule, refer to SOM for more details.
8.4.4.2 Blood Pressure
Systolic and diastolic blood pressure will be measured using an automated validated device 
with an appropriatel y sized cuff. In case the cuff sizes available are not large enough for the 
subject's arm circumference, a sphy gmomanometer with an appropriatel y sized cuff may be 
used.
The repeat sitting measurements will be made at up to 5 minute intervals and measurements 
will be recorded on the Vital Signs eCRF.
Refer to SOM for more details.
8.4.4.3 Body Temperature
Body temperature should be measured as per local practice –the same method to be used 
consistently  for all patients at each site.
Refer to SOM for more details.
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 90
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
8.4.7 Physical Examination
A complete physical examination should include the examination of general appearance, skin, 
neck , eyes, ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular and neurological systems. If indicated based on medical history  and/or 
symptoms, rectal, external genitalia, breast, and/or pelvic exams may be performed. 
Information for all phy sical examinations must be included in the source documentation at the 
study  site and will not be recorded on the eCRF. Significant findings that are present prior to 
informed consent are included in the CRF capturing Medical History . Significant findings 
observed after informed consent signature which meet the definition of an AE must be 
appropriatel y recorded on the appropriate CRF captu ring AEs.
8.4.9 Vaccination
If prior vaccination cannot be confirmed e.g. documented in subject’s medical notes, subjects 
enrolling must be vaccinated against N. meningitidis , S. pneumoniae and H. influenza . 
Toensure full protection, the vaccines against N. meningitidis should cover the most common 
seroty pes. 
Continuous close monitoring of subjects for early  symptoms and signs of meningococcal 
infection is required in order to evaluate subjects immedia tely if an infection is suspected.
CCI
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 91
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
8.5 Additional assessments
8.5.1 Clinical Outcome A ssessments (COA s)
8.5.2 Pharmacokinetics
PK samples will be collected at the time points defined in the Assessment schedule. The exact 
time point need to be recorded as well as missing samples.
Pharmacokinetic (PK) samples will be obtained and evaluated in all subjects at all dose levels.
For standard pharmacokinetic abbreviations and definitions see the list provided at the 
beginning of this protocol.
The following pharmacokinetic parameters of LNP023 will be determined using the actual 
recorded sampling times and non -compartmental anal ysis method(s) with Phoenix WinNonlin 
(Version 6.4 or higher):
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 92
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Plasma: Cmax, Tmax,, AUClast, AUCtau and Ctrough (Cmin) after the first dose on Day 7, 
Day 14, Day 21 and Day 28 as well as Cmin on Days 92and99(Week 13 and 14)
Urine: Non-compartmental parameters, including but not limited to total cumulative urinar y 
excretion (
Ue) and renal plasma clearance (CLr) of LNP023.
Other pharmacokinetic parameters may be calculated as appropriate. All parameters determined 
are considered at stead y state.
The linear trapezoidal rule will be used for AUC calculation. AUCtau will be calculated instead 
of AUCinf. Values below the lower limit of quantification will be treated as zero for calculation 
of PK parameters as well as for summary  statistics.
Further details on sample collection, 
numbering, processing and shipment will be provided in 
the lab manual and/or SOM.
8.5.3 Biomarkers
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 93
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confide ntial Page 94
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
9 Study  discontinuation and completion
9.1 Discontinuatio n
9.1.1 Discontinuation of study treatment
Discontinuation of study  treatment for a patient occurs when study  treatment is stopped earlier 
than the protocol planned duration. Discontinuation of study  treatment can be decided b y either 
the patient or the Investig ator. If discontinuation of study  treatment occurs, the investigator 
must determine the primary reason for the patient's premature discontinuation of study  
treatment and record this information on the Dosage Administration CRF.
Commercially Confidential Information
Novartis Confide ntial Page 95
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Patients who discontinue study treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent. Where possible, they should return for the assessments indicated by an asterisk 
(*) in the assessment table (safet y follow up and end of study  visits). If they fail to return for 
these assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) should be 
made to contact the patient/pre -designated contact as specified. This co ntact should preferabl y 
be done according to the study  visit schedule.
Cohort A
Study  treatment must be discontinued under the following circumstances:
Patient decision - Patients may  choose to discontinue study  treatment for any  reason at any  
time.
The In vestigator believes that continuation would negativel y impact the safety of the 
patient or the risk/benefit ratio of trial participation.
Any protocol deviation that results in a significant risk to the patient's safety .
Pregnancy
Infections that are considered, b y the investigator, not efficientl y manageable while being 
on LNP023
Worsening of C3G disease
Use of prohibited treatment as outlined in Table listing prohibited medications
Any laboratory  abnormalities that in the judgment of the investigator, tak ing into 
consideration the patient's overall status, prevents the patient from continuing participation 
in the study
Cohort B
Study  treatment must be discontinued under the same circumstances as Cohort A plus the 
below:
Histologic signs of graft rejection ≥ 2A BANFF and other signs of graft rejection that 
require increased doses of concomitant immunosuppressive therapies.
9.1.1.1 Replacement policy
Not applicable.
9.1.2 Withdrawal of informed consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a subject:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e-mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Novartis Confide ntial Page 96
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been co llected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
Novartis/sponsor will continue to keep and use collected study information (including an y data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law.
All biological samples not yet anal yzed at the time of withdrawal will no longer be used, unless 
permitted by  applicable law. They  will be stored according to applicable legal requirements.
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to co ntact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Study stopping rules
Novartis will review emergent safe ty reports on an ongoing basis to react as soon as there is a 
possibility  that a stopping rule could apply. The Sponsor will review all SAE as individual cases 
and will also be able to review summaries of non-serious adverse events for patterns and trends,
and will first exclude any events determined to be clearly  not related to LNP023 (e.g., SAE 
which occurred during the pre-treatment screening period, or disease -related SAE expected in 
the population under study).
Enrollment in the stud y and dosing of aff ected patient(s) with LNP023 will be paused if an y of 
the following occurs during the stud y:
One fatal or life -threatening SAE that is considered by the Investigator as potentially  
related to LNP023
OR two or more SAEs  that are considered b y the I nvestiga tor as potentially  related to 
LNP023 .
The study  may  resume following the safet y review, if the Investigator and Sponsor agree it is 
safe to proceed. Restart of this clinical trial in such case will be documented by  a substantial 
amendment and following approval by  relevant health authorities .
The Sponsor could decide to stop the enrollment for earl y success in Cohort A in case 50% will 
have normal C3 blood level s (≥ 900 mg/L) at Week 12.
Novartis Confide ntial Page 97
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
9.1.5 Early  study termination by  the sponsor
The study  can be terminated by the Sponsor at any time for any reason. This may include 
reasons related to the benefit/risk assessment of participating in the study , practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. In taking the decision to 
termina te, Sponsor will alway s consider the subject welfare and safety . Should early 
termination be necessary, subjects must be seen as soon as possible (provide instruction for 
contacting the subject, when the subject should stop taking drug, when the subject sh ould come 
for a final visit) and treated as a prematurel y withdrawn subject. The investigator may be 
informed of additional procedures to be followed in order to ensure that adequate consideration 
is given to the protection of the subject’s interests. The investigator or sponsor depending on 
the local regulation will be responsible for informing IRBs/IECs of the early termination of the 
trial.
9.2 Stud y completion and post -study  treatment
Study  completion is defined as when the last subject finishes his/her EOS visit, and any  repeat 
assessments associated with this visit have been documented and followed -up appropriatel y by 
the Investigator, or in the event of an earl y study termination decision, the date of that decision. 
In case patients willroll-over in theextension study , study  completion will occur at Visit 190 
All treated patients should have a safet y follow -up call conducted 30 days after last 
administration of study treatment. The information collected is kept as source documentation. 
All SAEs reported during this time period must be reported as described in Section 10.1.3 and 
SOM. Documentation of attempts to contact the subject sho
uld be recorded in the source 
documentation.
Continuing care should be provided by the investigator and/or referring physician based on 
subject availability  for follow -up. This care may include enrollment in an extension study , once 
available.
10 Safety  monit
oring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The Investigato r has the responsibility  for managing the safet y of individual subjects and 
identify ing adverse events.
Sponsor qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.
Commercially Confidential Information
Novartis Confide ntial Page 98
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
The occurrence of adverse events must be sought by non -directive questioning of the subject at 
each visit during the study. Adverse events also may be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  the following information (as far as possible) 
(if the event is serious refer to Section 10.1.2 ):
1.The severit y grade:
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.itsrelationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is th at the symptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y byan anal ysis of cohorts, not on a 
single subject
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (refer to Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.action taken regarding study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose reduced/i ncreased
Drug interrupted/withdrawn
its outcome 
a)not recovered/not resolved;
b)recovered/resolved;
c)recovering/resolving;
d)recovered/resolved with sequelae;
e)fatal; or unknown.
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 days (or 5 half-lives or end of 
study  visit, whichever is longer) following the last dose of study  treatment.
Novartis Confide ntial Page 99
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Information about adverse drug reactions for the investigational drug can be found in the IB.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in subjects with 
the underl ying dise ase. 
Follow the instructions found in the SOM for data capture methodology  regarding AE collection 
for subjects that fail screening.
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically  might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpat ient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
treatment on an emergency  outpatie nt basis for an event not fulfilling an y of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
Novartis Confide ntial Page 100
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  or abuse.
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met .
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
even t irrespective if a clinical event has occurred.
10.1.3 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 days after the last study  visit must be reported to 
Sponsor safet y within 24 hours of learning of its occurrence. Detailed instructions regarding the 
submission process and requirements are to be found in the investigator folder provided to each 
site.
Consider the following 3 categories (as applicable) to determine SAE reporting timeframes:
1.Screen Failures: SAEs occurring after the subject has provided informed consent until the 
time the subject is deemed a Screen Failure must be reported to Sponsor.
2.Run-in Failures: SAEs collected between time subject signs ICF unt il time that subject is 
determined to be a run -in failure.
3.Treated Subjects: SAEs collected between time subject signs ICF until 30 days after the 
subject has discontinued or stopped study  treatment (or longer, depending on the 
elimination half -life of LNP 023).
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the investigator receiving the follow -up info rmation. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. The Sponsor may need to issue an Investigator Notific ation (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day period after the last intervention or-treatment follow -up 
visits with no required proce dures should onl y be reported to Sponsor Safety if the investigator 
suspects a causal relationship to study  treatment.
Novartis Confide ntial Page 101
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
10.1.4 Pregnancy  reporting
To ensure subject safety, each pregnancy occurring after signing the informed consent must be 
reported to Sponsor within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or mater nal 
and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the Sponsor Chief Medical 
Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of thepossible relationship to the investigational 
treatment an y pregnancy  outcome. Any  SAE experienced during pregnancy must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in acco rdance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in t he protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 hours of I nvestigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misus e/abuse
Treatment error type Document in Dose 
Administration (DA R) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.
Novartis Confide ntial Page 102
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
10.2 Additional Safety  Monitoring
10.2.1 Liver safety monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 16-1in Appendix 1 for complete definitions of liver laboratory  triggers 
and liver events.
Every  liver event defined i n Table 16-1should be followed up by the investigator or designated 
personnel at t he trial site, as summarized below. Additional details on actions required in case 
of liver events are outlined in Table 16-2. Repeat liver chemistry tests (ALT, AST, TBL, 
PT/INR, ALP and G -GT) to confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. If results will 
not be available from the central laboratory , then the repeats can also be performed at a 
local laboratory  to monitor the safet y of the subject. If a liver event is subsequently  
reported, any local liver chemistry  tests previously  conducted that are associated with this event 
should have results reported on the unplanned local laboratory  CRF (or liv er CRF page )
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate
Discontinuation of the investigational drug (refer to Section 9.1.1 ), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event should include 
These investigations can include based on investigator’s discretion: serology tests, 
imaging and pathology  assessments, hepatologist’s consultancy ; obtaining more 
detailed history  of sy mptoms and prior or concurrent diseases, history  of concomitant 
drug use, exclusion of underly ing liver disease
All follow -up information, and the procedures performed must be recorded as appropriate in 
the CRF.
Refer to the Site Operations Manual for additional details.
10.2.2 Renal safety  monitoring
Renal safet y monitoring is alread y performed as part of the stud y endpoints. 
Novartis Confide ntial Page 103
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
10.2.3 Infection Surveillance
All infections that develop during the study  will be reported as AEs. Investigators are requested 
to specifically  enquire about signs and symptoms of infections at each visit, in particular for 
encapsulated bacteria. 
Other additional evaluations will be performed at the discretion of the Investigator.
11 Data Collection and Database management
11.1 Data collection
All data should be recorded, handled and stored in a way that allows accurate reporting, 
interpretation and verification.
Designated investigator staff will enter the data required by the protocol into the Electronic Case 
Report Forms (eCRF). The eCRFs have been built using fully validated secure web-enabled 
software tha t conforms to 21 CFR Part 11 requirements, Investigator site staff will not be given 
access to the EDC system until they have been trained. Automatic validation programs check 
for data discrepancies in the eCRFs, allow modification and/or verification of t he entered data 
by the investigator staff.
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry  and updates are performed in a timely  manner. 
The Investigator must certify  that the data entered are complete and accurate.
Certain data may be captured via other source documentation (such as safety  laboratory  data 
report, imaging) and then transcribed, uploaded or transferred into the system. This, and any 
additional da ta treated in this manner, will be source data verified by  the study  monitor per the 
monitoring plan and the location of source data (i.e., source, paper or a local electronic system) 
will be documented prior to study  start in the Data Quality  Plan. The system has the ability  to 
illustrate when a document has been entered from another source. When using an electronic 
source record as the original point of data capture, there is no additional data entry  step for the 
site for data collected directly  into the application; rather, the electronic source record directl y 
populates the study  database.
Automatic validation programs check for data discrepancies and, by generating appropriate 
error messages, allow the data to be confirmed or corrected before transfer of the data to the 
vendor working on behalf of Novartis.
Remote monitoring of the original electronic source records 
will take place, however on-site 
monitoring inspections will continue to take place in order to review data entry  of source 
documentation directly  captured on paper and transcribed into the system , to ensure protocol 
Commercially Confidential Information
Novartis Confide ntial Page 104
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
adherence, to assess site operational capabilities, and to perform other monitoring activities that 
cannot be performed remotely .
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
11.2 Database management and quality  control
Sponsor personnel (or designated CRO) will review the data entered by investigational staff for 
completeness and accuracy . Electronic data queries stating the nature of the problem and 
requestin g clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Conc omitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked. Any changes to the database after that time can only 
be made after written agreement b y Sponsor development management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a Sponsor or 
delegated CRO representative will review the protocol and data capture requirements 
(i.e., eSource DDE or eCRFs) with the investigators and their staff. During the study , Sponsor 
employ s several methods of ensuring protocol and GCP compliance and the quality /integrity  of 
the sites’ data. The field monitor will visit the site to check the completeness of subject records, 
the accuracy  of data capture / data entry , the adherence to the protocol and to Good Clinical 
Practice, the progress of enrollment, and to ensure that study  treatment is being stored, 
dispensed, and accounted for according to specifications. Key study personnel must be available 
to assist the field monitor during these visits. Continuous remote monitoring of each site’s data 
may be performed by a centralized Sponsor or delegated CRO or CRA organization. 
Additionally , a central analy tics organization may analyze data & identify  risks & trends for 
site operational parameters, and provide reports to Sponsor clinical teams to assist with trial 
oversight.
Commercially Confidential Information
Novartis Confide ntial Page 105
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data, electrocard iograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
subject’s file. The Investigator must also keep the original informed consent form signed by the 
subject (a signed cop y is given to the subject).
The Investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Sponsor monitoring standards require full 
verification for the presence of informe d consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. 
Additional checks of the consistency  of the source data with the CRFs are performed according 
to the study -specific monitoring plan. No information in source documents about the identity 
of the subjects will be disclosed.
12 Data analy sis and statistical methods
Any data anal ysis carried out independently  by the investigator should be submitted to Sponsor 
before publication or presentation. The data analysis includes data generated from Screening, 
Treatment period  and safet y Follow -up periods
12.1 Analysis sets
For all anal ysis sets, subjects will be analy zed according to the study  treatment(s) received for 
Cohort A and B.
The safet y analysis set will include all subjects that received any  stud y drug.
The PK anal ysis set will include all subjects with available PK data and no protocol deviations 
with relevant impact on PK data.
The PD anal ysis set will include all subjects with available PD data and no protocol deviations 
with relevant impact on PD data.
12.2 Subject demographics and other baseline characteristics
Demographic and other baseline data including disease characteristics will be listed by  subject 
and summarized descriptively  for all subjects for the safet y set.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, minimum, and maximum will be presented. For selected parameters, 
25th and 75th percentiles will also be presented.
Relevant medical histories and current medical conditions at baseline will be summarized 
(separatel y) by system organ class and preferred term, for all subjects.
Relevant medical history, current medical conditions, results of laboratory screens, drug tests 
and an y other relevant information will be li sted by subject.
CCI
Commercially Confidential Information
Novartis Confide ntial Page 106
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
12.3 Treatments
The Safet y set will be used for the anal yses below.
Categorical data will be summarized as frequencies and percentages. For continuous data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
Data for study  drug administration will be listed by subject and summarized by treatment group.
Summary  includes:
Number of subjects who took all the planned doses of LNP023
Concomitant medications and significant non-drug therapies prior to and after the start of the 
study  treatment will be listed and summarized according to the Anatomical Therapeutic 
Chemical (ATC) classification sy stem, for all subjects.
12.4 Analysis of the primary  endpoint(s)
The primary  objectives of this study  are:
Cohort A: To evaluate the efficacy  of LNP023 in reducing proteinuria at week 12, as assessed 
by Ratio to baseline of Urine Protein to Creatinine concentration Ratio derived from 24 -h urine 
collection in C3G patients who have not received a kidney  transplantation and have reduced C3 
blood levels.
Cohort B: To assess histopathological changes in kidney  biopsies at Week 12, as assessed by 
change from baseline in C3 Deposit Score (based on immunofluorescence microscop y) in C3G 
patients who have received a kidney  transpl antation.
12.4.1 Definition of primary  endpoint(s)
The primary  endpoints of this study  are
Cohort A: Reduction from baseline in UPCR at Week 12
Cohort B: Change from baseline in C3 Deposit Score (based 
on immunofluorescence 
microscop y) at Week 12
12.4.2 Statistical model, hypothesis, and method of analy sis
12.4.2.1 Statistical A nalysis:
Cohort A
The primary  variable for assessing the effect of LNP023 is the log ratio to baseline UPCR 
derived from the 24h urine collections at Week 12 .
A mixed model repeated measures (MMRM) will be fitted to the log ratio to baseline UPCR 
values over time. The model will include the log ratio to baseline UPCR as the dependent 
variable ,time point (as study  day relative to the start of study  treatment) as a fixed effect, and 
baseline log transfor med UPCR as a fixed covariate.
Novartis Confide ntial Page 107
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Baseline is defined to be the 24h urine collection on Day -1 to Day 1. An unstructured 
covariance matrix will be used.
Results from this modelling will be presented as the estimated mean value of log UPCR at week 
12 together with the 80% confidence interval. The results will be back transformed to provide 
the geometric mean and their 80% CIs on the original scale.
Cohort B
The primary variable for assessing the histopathological changes in kidney biopsies is week 12 
change from baseline C3 Deposit Score.
The Wilcoxon signed rank test will be used for C3 Deposit Score data at Week12 time point to 
compare the median difference of change from baseline. The Hodges -Lehmann estimate and 
80% confidence interval for the median differen ce will be provided.
12.4.3 Handling of missing values/censoring/discontinuations
The primary  anal ysis will include all available data up to the point of treatment discontinuation 
for patients who discontinue.
 Subjects with missing UPRC or C3 Deposit Score values will still be included in the 
mixed model analy sis with such data assumed missing at random (MAR).
Given the severe nature of the indication and the need for close monitoring it is expected that 
there will be very  little truly  missing data.
12.4.4 Sensitivity analy ses
12.5 Analysis of secondary  endpoints
The secondary  variables supporting the secondary objective are provided below:
Biomarkers:
Including blood levels of C3, Bb.
PD variables:
urine UPCR.
Renal parameters UA, UACR, UP, UPCR, serum creatinine, eGFR (using the CKD -EPI
formula), creatinine clearance, hematuria.
Ratio to baseline of UPCR and UACR derived from 24- h urine collection
Safety variables:
Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 108
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
ECG, vital signs, safet y laboratory  assessments , AEs 
and SAEs.
PK variables:
Total drug PK parameters, including Tmax, Cmax, AUClast and AUCtau, as well as Ctrough 
(pre-dose) after multiple doses and total cumulative urinary  excretion (Ue) and renal plasma 
clearance (CLr).
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
The secondary variables supporting the secondary objective to assess the effect of LNP023 on 
renal function are 24-h UA, UACR, 24-h UP, UPCR, serum creatinine, eGFR, creatinine 
clearance, hematuria.
These variables will each be anal yzed with the same MMRM as used for the primary  variable.
Additionally  the ratio to baseline of UPCR and UACR derived from 24 -h urine collection will 
also be anal yzed w ith the same MMRM (only  Cohort B).
Appropriate transformations will be detailed in the SAP.
12.5.2 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
subject.
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary  for death including on-treatment and 
post-treatment deaths will be provided. I n particular, summary  tables for adverse events (AEs) 
will summarize only on
-treatment events, with a start date during the on-treatment period 
(treatment -emergent 
AEs).
The on -treatment period lasts from the date of first administratio n of study  treatment to 30 days 
after the date of the last actual administration of any  study  treatment.
Adverse events
All information obtained on adverse events will be display ed by treatment group and patient.
The number (and percentage) of subjects with treatment emergent adverse events (events started 
after the first dose of study  medication or events present prior to start of treatment but increased 
in severity  based on preferred term) will be summarized in the following way s:
by treatment, primary  system organ class and preferred term.
by treatment, primary  system organ class, preferred term and maximum severity .
by treatment, Standardized MedDRA Query  (SMQ) and preferred term
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation and adverse events 
leading to dose adjustment.
CCI
Novartis Confide ntial Page 109
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
A subject with multiple adverse events within a primary  system organ class is only counted 
once towards the tota l of the primary  system organ class.
Adverse events which will be counted for a specific treatment period are those which are 
treatment -emergent. These events are those with an onset after the start of the treatment period, 
or which were present prior to the start of the treatment period but increased in severity , changed 
from being not suspected to being suspected of study  drug relationship, or developed into SAEs 
after the start of the treatment period.
Vital signs
All vital signs data will be listed by treatment group, patient, and visit/time and if ranges are 
available, abnormalities will be flagged.
Summary  statistics will be provided by  treatment and visit/time.
12-lead ECG
All ECG data will be listed by treatment group, subject and visit/time, abnorma lities will be 
flagged. Summary  statistics will be provided by treatment and visit/time and the number of 
patients with values above key  threshold values will be display ed.
Clinical laboratory  evaluations
All laboratory  data will be listed by treatment group, subject, and visit/time and if normal ranges 
are available abnormalities will be flagged.
Summary  statistics will be provided by treatment and visit/time. Shift tables using the 
low/normal/high/ (low and high) classification will be used to compare baseline to the worst 
on-treatment value.
Other safety  evaluations
Include or omit as relevant for any additional safet y parameters –describe the listings, 
summaries and/or graphical output.
12.5.3 Pharmacokinetics
Individual LNP023 plasma/urine concentration data will be listed by treatment, subject, and 
visit/sampling time point, and plotted over time by  subject.
Summary  statistics will include mean (arithmetic and geometric), SD, CV (arithmetic and 
geometric), median, minimum and maximum. 
A geometric mean will not be 
reported if the dataset includes zero values.
All individual plasma concentration
-time profiles for LNP023 concentration with median will 
be display ed graphicall y by treatment on semi -log view. In addition, the mean (+/-SD) and 
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 110
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
geometric mean plasma concentration -time profiles for LNP023 b y treatment over time will be 
display ed graphically  on the linear and semi -log view.
Pharmacokinetic parameters will be calculated as described in Section 8.5.2 and will be listed 
by treatment and subject.
Descriptive summary  statistics will include mean (arithmetic and geometric), SD, and CV 
(arithmetic and geometric), median, minimum and maximum. An exception to this is Tmax 
where median, minimum a nd maximum will be presented.
12.5.4 Biomarkers
All biomarker data (except for hypothesis -free platforms) will be listed by treatment, subject, 
and time. Summary  statistics will be provided by  treatment and time.
Graphical measures will be used to explore relationships between LNP 023 treatment and 
biomarkers.
Additionally  graphical measures will be used to assess the relationships between chang es in 
proteinuria and biomarker over time.
12.5.5 PK/PD relationships
Efficacy  biomarkers analy sed during this study  will be plotted against individual PK parameters 
such as Cmax or AUC as well as against administered dose to establish the exposure/ response 
relationship and to determine the (lowest) efficacious dose or exposure.
12.6 Analysis of exploratory  endpoints
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 111
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confide ntial Page 112
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
12.7 Interim analy ses
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 113
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
12.8 Sample size calculation
12.8.1 Primary  endpoint(s)
Cohort A -Primary  Endpoint: Reduction from baseline in log transformed UPCR.
a sample size of 15 subjects provides 93% power that the 
primary  analysis will be statistically  significant at the one-sided 10% significance level 
assuming 20% of losses to follow -up.
Cohort B-Primary  Endpoint: Change from baseline in C3 Deposit Score (based on 
immunofluorescence microscop y).
 a sample size of 12 subjects provides 94% 
power that the primary  analysis will be statistically  significant at the one-sided 10% significance 
level assuming 17% of losses to follow -up.
13 Ethical considerations and administrative proc edures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (including E uropean Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opinion from 
the Institutional Review Board/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subjec t recruitment procedures 
(e.g., advertisements) and any other written information to be provided to subjects. Prior to 
study  start, the Investigator is required to sign a protocol signature page confirming his/her 
agreement to conduct the study  in accordance with these documents and all of the instructions 
and procedures found in this protocol and to give access to all relevant data and records to 
Sponsor monitors, auditors, Sponsor Quality  Assurance representatives, designated agents of 
Sponsor, I RBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site 
is requested bya regulatory  authority , the Investigator must inform Sponsor immediately  that 
this request has been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov and 
as require d in EudraCT. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial 
results, such as the Novartis clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.).
Commercially Confidential Information
Commercially Confidential Information
Novartis Confide ntial Page 114
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
For details on the Sponsor publication policy  including authorship criteria, please refer to the 
Sponsor publication pol icy training materials that were provided to you at the trial investigator 
meetings
13.4 Qualit y Control and Quality  Assurance
Sponsor maintains a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and Sponsor systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Sponsor processes.
14 Protocol adherence
This protocol defines the study  objectives, the study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety of subjects should be 
administered as deemed necessary  on a case by case basis. Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by Sponsor 
and approved by the IR B/IEC and health authorities, where required, it cannot be implemented.
14.1 Protocol A mendments
Any change or addition to the protocol can only be made in a written protocol amendment that 
must be approved by Sponsor, health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediate ly 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local r egulations.
Novartis Confide ntial Page 115
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
15 References
References are available upon request
Alanee SR, McGee L, Jackson D, et al (2007) Association of serot ypes of Streptococcus 
pneumoniae with disease severity and outcome in adults: an international study. Clin Infect 
Dis; 46 -51.
Barbo ur TD, Pickering MC, Terence Cook H (2013) Dense deposit disease and C3 
glomerulopath y. Semin Nephrol ; 493-507.
Bentall A, T yan DB, Sequeira F, et al (2014) Antibody -mediated rejection despite inhibition 
of terminal complement. Transpl Int; 1235-43.
Bombac k AS, Radhakrishnan J (2014) The evolution of treating glomerular diseases: letting 
science lead the way . Adv Chronic Kidney  Dis; 119 -20.
Bomback AS, Santoriello D, Avasare RS, et al (2018) C3 glomerulonephritis and dense 
deposit disease share a similar disease course in a large United States cohort of patients with 
C3 glomerulopath y. Kidney Int; 977-985.
Bomback AS, Smith RJ, Barile GR, et al (2012) Eculizumab for dense deposit disease and C3 
glomerulonephritis. Clin J Am Soc Nephrol; 748-56.
Braun MC, Sta blein DM, Hamiwka LA, et al (2005) Recurrence of membranoproliferative 
glomerulonephritis ty pe II in renal allografts: The North American Pediatric Renal Transplant 
Cooperative Study  experience. J AmSoc Nephrol ; 2225-33.
Bryant KA, Frenck R, Gurtman A, et al (2015) Immunogenicit y and safety of a 13 -valent 
pneumococcal conjugate vaccine in adults 18- 49 years of age, naive to 23 -valent 
pneumococcal poly saccharide vaccine. Vaccine ; 5854 -5860.
Couser WG, Riella MC, Abraham G, et al (2011) World Kidney  Day  2011 : protect your 
kidney s, save y our heart. Rev I nvest Clin ; 8-11.
Fellström BC, Barratt J, Cook H, et al (2017) Targeted -release budesonide versus placebo in 
patients with IgA nephropathy  (NEFIGAN): a double -blind, randomised, placebo- controlled 
phase 2b tri al. Lancet ;2117 -2127.
Floege J, Moura IC, Daha MR (2014) New insights into the pathogenesis of IgA nephropath y. 
Semin I mmunopathol ; 431 -42.
Goodship TH, Cook HT, Fakhouri F, et al (2017) Aty pical hemoly tic uremic sy ndrome and 
C3 glomerulopath y: conclusion s from a "Kidney  Disease: Improving Global Outcomes" 
(KDIGO) Controversies Conference. Kidney  Int; 539-551.
Gossger N, Snape MD, Yu L M, et al (2012) I mmunogenicity  and tolerability  of recombinant 
serogroup B meningococcal vaccine administered with or witho ut routine infant vaccinations 
according to different immunization schedules: a randomized controlled trial. JAMA ; 573-82.
Jha V, Rathi M (2013) Dialy sis: low -glucose -containing peritoneal dial ysis solutions: good or 
bad? Nat Rev Nephrol; 635-6.
Novartis Confide ntial Page 116
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
KDIGO (201 2) Kidney  Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis 
Work Group. KDIGO Clinical Practice Guideline for Glomer ulonephritis. Kidney  Int; 
2:139 -274.
Keyserling H, Papa T, Korany i K, et al (2005) Safety , immunogenicit y, and immune memory 
of a novel meningococcal (groups A, C, Y, and W -135) poly saccharide diphtheria toxoid 
conjugate vaccine (MCV -4) in health y adolescents. Arch Pediatr Adolesc Med ; 907-13.
Kirschfink M, Mollnes TE (2003) Modern complement anal ysis. Clin Diagn L ab Immunol ;
982-9.
Konar M, Granoff DM (2017) Eculizumab treatment and impaired opsonophagocy tic killing 
of meningococci b y whole blood from immunized adults. Blood ; 891-899.
Kościelska -Kasprzak K, Bartoszek D, M yszka M, et al (2014) The complement cascade and 
renal disease. Arch Immunol Ther Exp (Warsz.) ; 47-57.
Levey  AS, Stevens LA, Schmid CH, et al (2009) A new equation to estimate glomerular 
filtration rate. Ann Intern Med; 604-12.
MacNeil JR, Cohn AC, Farley  M, et al (2011) Current epidemiology  and trends in inva sive 
Haemophilus influenzae disease --United States, 1989- 2008. Clin I nfect Dis ; 1230-6.
Maillard N, Wy att RJ, Julian BA, et al (2015) Current Understanding of the role of 
complement in IgA Nephropathy. J Am Soc Nephrol ; 1503-12.
Mathern DR, Heeger PS (2015 ) Molecules great and small: The complement sy stem. Clin J 
Am Soc Nephrol ; 1636 -50.
Matsumoto M (1999) Functional anal ysis of non-HLA genes within MHC region with 
knockout -mouse technology . Seikagaku ; 323-32.
McFetridge R, Meulen AS, Folkerth SD, et al (20 15) Safet y, tolerabilit y, and immunogenicit y 
of 15 -valent pneumococcal conjugate vaccine in healthy  adults. Vaccine ;2793 -9.
Medjeral -Thomas NR, O'Shaughness y MM, O'Regan JA, et al (2014) C3 glomerulopathy: 
clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol ; 46-53.
Nester CM, Smith RJ (2016) Complement inhibition in C3 glomerulopathy. Semin I mmunol ;
241-9.
Pickering MC, D'Agati VD, Nester CM, et al (2013) C3 glomerulopath y: consensus report. 
Kidney  Int; 1079 -89.
Riedl M, Thorner P and Licht C (2017) C3 Glomerulopathy . Pediatr Nephrol ;32(1):43-57.
Ruggenenti P, Cravedi P, Remuzzi G (2007) Latest treatment strategies for membranous 
nephropathy. Expert Opin Pharmacother ; 3159- 71.
Salvadori M, Bertoni E (2016) Complement related kid ney diseases: Recurrence after 
transplantation. World J Transplant ; 632-645.
Savige J, Amos L , Ierino F, et al (2016) Retinal disease in the C3 glomerulopathies and the 
risk of impaired vision. Ophthalmic Genet ; 369- 376.
Novartis Confide ntial Page 117
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Servais A, Noël LH, Roumenina LT, e t al (2012) Acquired and genetic complement 
abnormalities play  a critical role in dense deposit disease and other C3 glomerulopathies. 
Kidney  Int; 454 -64.
Sethi S, Vrana JA, Fervenza FC, et al (2017) Characterization of C3 in C3 glomerulopath y. 
Nephrol Dia l Transplant ; 459 -465.
Skattum L , van Deuren M, van der Poll T, et al (2011) Complement deficiency  states and 
associated infections. Mol I mmunol ; 1643-55.
Slade C, Bosco J, Unglik G, et al (2013) Deficiency  in complement factor B. N Engl J Med ;
1667 -9.
Sridhar S, Greenwood B, Head C, et al (2015) Global incidence of serogroup B invasive 
meningococcal disease: a sy stematic review. Lancet I nfect Dis ; 1334 -46.
Stegall MD, Diwan T, Raghavaiah S, et al (2011) Terminal complement inhibition decreases 
antibody -mediated rejection in sensitized renal transplant recipients. Am J Transplant. p. 
2405 -13.
Thomas S, Ranganathan D, Francis L, et al (2014) Current concepts in C3 glomerulopath y. 
Indian J Nephrol p. 339 -48.
Webster AC, Nagler EV, Morton RL , et al (2017) Ch ronic Kidney  Disease. L ancet ;
1238 -1252.
Zand L, Lorenz EC, Cosio FG, et al (2014) Clinical findings, pathology , and outcomes of 
C3GN after kidney  transplantation. J Am Soc Nephrol; 1110 -7.
Zhang Y, Nester CM, Martin B, et al (2014) Defining the complement biomarker profile of 
C3 glomerulopath y. Clin J Am Soc Nephrol ; 1876-82.
Novartis Confide ntial Page 118
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
16 Appendices
Commercially Confidential Information
Novartis Confide ntial Page 119
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confide ntial Page 120
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information
Novartis Confide ntial Page 121
Amended Protocol Version v03 ( Clean ) Protocol No. CLNP023X2202
Commercially Confidential Information